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ABSTRACT 
Chronic pain of various origins is a major health care issue affecting a large patient population, 
also bring significant social and economic cost on the society. Work presented in this thesis 
concerns novel methods of treatments for chronic pain using experimental models. Sinomenine 
is a chemical compound isolated originally from the root of the plant Sinomenium Acutum 
native to China and Japan. It is an alkaloid, structurally belongs to the morphine family. The 
root of Sinomenium Acutum, known as Qingteng, has been traditionally used in China as a 
medical remedy for condition likely to be rheumatism. Sinomenine is currently approved in 
China as an anti-rheumatic agent for clinical sue.  
In first part of the thesis, we studied the analgesic effect of sinomenine in chronic experimental 
pain models of neuropathic and arthritic pain. We showed that sinomenine has significant 
analgesic effects in rat and mouse models of neuropathic pain as well as in a mouse model 
(collagen antibody-induced arthritis model, CAIA) of arthritic pain. More importantly, the 
effect of sinomenine on neuropathic and arthritic pain is maintained upon repeated chronic 
administration without signs of tolerance or dependence.  
In the second part of the thesis, we examined the possible application of sinomenine as an 
analgesic, we showed that combination with sinomenine with gabapentin, a clinically used drug 
treating neuropathic pain, produced marked synergistic interaction in rat and mouse models of 
neuropathic pain and such synergism can still be observed upon repeated administration 
without signs of tolerance and dependence. We can also show a similar synergistic interaction 
between gabapentin and dextromethorphan, a low affinity non-competitive NMDA antagonist.  
The work presented in this thesis suggested that sinomenine could be explored as a novel 
analgesic in treating neuropathic and arthritic pain. The results also showed combination 
therapy involving sinomenine, gabapentin and dextromethorphan might be useful in the clinic. 
The potential mechanisms for the effect of sinomenine and its interaction with other analgesics 
need to be further studied. 
 
Key words: Sinomenine, Neuropathic Pain, Arthritic Pain, Gabapentin, Dextromethorphan, 
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1 INTRODUCTION 
1.1 CLASSIFICATION OF PAIN 
Pain has been known to mankind from the very beginning and is perhaps the oldest medical 
problem. Hippocrates, the great Greek physician, suggested that pain may cause by disturbance 
of the four-body humor’s (blood, phlegm, yellow bile and black bile). He even wrote that 
willow leaves and bark can relieve pain which we know today contain salicylic acid. Yet, until 
very recently, little is known about the physiology of pain and the underlying mechanisms of 
pain management. Such advancement has been helped in large by our improved understanding 
of the classification of pain. 
There are many ways to classify pain which can be based on, for example, location reference, 
and type of tissue involved or duration of pain. The most important classification of pain, one 
that bares major implication for mechanisms and treatments, is based on the causes of pain 
which can be divided into three major categories: nociceptive pain, inflammatory pain and 
neuropathic pain (Woolf, 2004).  
Nociceptive pain is an unpleasant sensory experience generated by noxious stimuli that is 
potentially tissue damaging.  Noxious stimuli can have various qualities (i.e. mechanical, heat, 
cold stimuli or chemical). The ability of the organisms to sense nociceptive stimuli is essential 
for its survival to prevent imminent tissue damage in the environment. Therefore, nociceptive 
pain plays a significant role as alarm system. In most cases, nociceptive pain is acute because 
once noxious stimuli was removed,  the pain stops (Scholz & Woolf, 2002). 
Inflammatory pain is a pain associated with inflammatory process such as tissue trauma, 
ischemia, infections, tumor growth and autoimmune diseases. A variety of chemical mediators 
such as cytokines, growth factors, kinase, purines, amines, prostanoid and protons release from 
damaged/inflammatory cells (Boddeke, 2001; Mantyh et al., 2002) that either directly activate 
nociceptors or increase the sensitivity of sensory nervous system to facilitate pain perception 
(Scholz & Woolf, 2002). Duration of inflammatory pain can be either acute, intermediate or 
chronic. 
Neuropathic pain is a pain initiated or caused by a primary lesion or dysfunction of the nervous 
system (Costigan et al., 2009; Merskey & Bogduk, 1994). Such lesion or dysfunction can occur 
in the peripheral nerve system such as in the cases of metabolic disorders, mechanical trauma, 
neurotoxic chemicals, infection or tumor invasion (Decosterd et al., 2002). On the other hand, 
in situations such as spinal cord injury, stoke, or multiple sclerosis, central neuropathic pain 
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may occur (Ducreux et al., 2006). In the majority of cases, neuropathic pain is chronic, difficult 
to manage and inevitably associated with plastic changes of the nervous system (Hokfelt et al., 
1994). The characteristic of neuropathic pain may include spontaneous pain, allodynia and 
hyperalgesia (Woolf & Mannion, 1999). 
1.2 CHRONIC PAIN 
Any pain that lasts more than three months is usually considered as chronic pain. Chronic pain 
is a major health problem accompany a large number of diseases involving a board patient 
population. Common conditions, such as rheumatoid arthritis (RA), diabetes and cancer are 
often associated with severe pain that may last a large part of patient’s life span. The same is 
also true for chronic neuropathic pain (Andersson, 2004; Breivik et al., 2006). Chronic pain 
brings much suffering because of its severity and persistence. In European countries, 19% of 
adults suffer from moderate to severe intensity chronic pain, which seriously reduce their life 
quality of patients’ affected (Breivik et al., 2006). The treatment of chronic pain, especially the 
origin of neuropathic pain, remains an urgent challenge. Although research in animal models 
have been developed for long term, few analgesics are available to treat the neuropathic pain, 
and do not reach the effective level of pain relief in many patients. Further, long-term 
application of analgesics may lead to drug tolerance, dependence and abuse. 
1.2.1 Neuropathic pain 
 Nerve damage at any level, be it central or peripheral, could cause the neuropathic pain. 
Neuropathic pain also arises from any numbers of particular conditions (Jensen et al., 2001) , 
such as post-herpetic neuralgia, nerve root avulsion, diabetic neuropathy, central neuropathic 
pain syndrome, post-operative pain syndrome (such as post-mastectomy syndrome, phantom 
limb pain) and complex regional pain syndrome (CRPS) (Colloca et al., 2017). In addition to 
ongoing pain which can have various qualities, typical symptom of neuropathic pain may also 
include sensory loss, sensory disturbances as well as other paresthesia such as hyperesthesia, 
hyperalgesia and allodynia. Pain and other sensory symptoms in neuropathic pain generally 
last a long time and often persist even after primary lesions have recovered.  
1.2.2 Chronic pain in Rheumatoid arthritis 
Rheumatoid arthritis is a chronic inflammatory, autoimmune disease in which the patient's 
immune system attacks its own (mostly in this case) joint tissues (Smolen & Steiner, 2003). 
Smaller joints of the hands and feet are often first affected and as disease progresses, other 
larger joints or other tissues may also be affected. Symptoms usually include pain, swelling, 
and stiffness with various dysfunctions. Rheumatoid arthritis affects 0.5-1.0% world 
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population and most common prevalent in patients between 20-50 years old. A large portion 
of patients with rheumatoid arthritis (RA) patients consider pain as one of their top three 
priorities (Heiberg et al., 2005). Gender is an important factor with female patients are about 
three times as many as male patients (Scott et al., 2010). Genetic inheritance also play an 
important role in rheumatoid arthritis with the HLA-DRB1 genotype identified in the 
pathogenesis of rheumatoid arthritis (Liu et al., 2016; Scott et al., 2010; Wolfe & Michaud, 
2007). The joint dysfunction and pain is RA patients are often not due to the direct damage of 
cartilage or bone, but rather indirect effect of the autoimmune reaction affecting the inner layer 
of the joint capsule by inflammatory mediators such as prostaglandins and cytokines. It will 
activate and sensitize nociceptors in the joints, leading to spontaneous joint pain, pain 
associated with movement or on palpation and hyperalgesia (Bas et al., 2012). With the 
progression of diseases, it will eventually damage the structure of joint cartilage, bone and 
nerves, producing chronic regional and/or wide spread pain in a significant percentage of these 
patients (Andersson et al., 2013). Pain in many patients is neuropathic pain in nature. 
Fibromyalgia is particular type of chronic widespread pain and In RA patients, it has 
significantly higher prevalence  than general population (Lee, 2013).  
In order to achieve effective relief of symptoms or reduce the disease process, rheumatoid 
arthritis treatment usually begins in the early stage. The primary goal is to improve the quality 
of life by reducing pain and inflammation, while slowing or preventing the development of 
permanent damage. Many drugs, particularly the new biologic drugs, have shown significant 
anti-inflammatory effect, preventing the development of inflammation by blocking the 
cytokines pathway or action of immune cells. However, these drugs have unintended side 
effects, such as an increased risk of infection. Despite this, pain management, especially for 
chronic pain, is still a challenge in many RA patients (Andersson et al., 2013; Lee, 2013). 
1.3 ANIMAL MODELS OF CHRONIC PAIN 
The development and continuous improvement of the animal pain models is important for 
study of the mechanisms and treatments of chronic pain.  In the field of neuropathic pain, the 
chronic nerve constriction model as reported by Bennett and Xie (1988) (Bennett & Xie, 1988) 
was very important as they showed that it is possible to produce a partial injury to the sciatic 
nerve, enabling studies of stimulation induced behaviors similar to human conditions of 
hyperalgesia and allodynia. As a result, a large number of animal models has been developed 
using a variety of methods to induce injury in different nerves, greatly facilitating the 
experimental research on neuropathic pain (Xu & Wiesenfeld-Hallin, 2003).  
 4 
Our laboratory has developed several rodent models of neuropathic pain after ischemic injury 
to the spinal cord, sciatic nerve and infraorbital nerve and many features of these models are 
similar to clinical pain conditions in patients with neuropathic pain conditions, such as spinal 
cord injury pain, diabetic neuropathy and trigeminal neuralgia. The ischemic injury is produced 
by an intravascular photochemical interaction between a photosensitizing dye and a laser beam, 
leading to the generation of singlet oxygen radicals at the endothelial cells of capillaries and 
subsequent platelet aggregation within the blood vessels in the irradiated tissues (Kupers et al., 
1998; Watson et al., 1986). Using this technique, our laboratory developed one of the first 
animal model of central neuropathic pain after spinal cord injury (SCI) (Xu et al., 1992). Thus, 
after spinal ischemic injury rats developed marked pain-like behaviors to mechanical and cold 
stimulation in the dermatomes corresponding to injured spinal segments which is similar to 
SCI patients(Hao et al., 1991, 1992; Xu et al., 1992; Xu et al., 1994). This model has been used 
to test the efficacy of a large number of analgesics against central neuropathic pain. The 
photochemical technique has also been used in producing partial sciatic nerve injury in rats and 
mice (Hao et al., 2000a; Kupers et al., 1998) and infraorbital nerve injury in rats (Eriksson et 
al., 2005). We have used these models in the work presented in this thesis. 
Several rodent models of RA are available primarily based on the pathophysiological 
mechanisms of RA. The adjuvant arthritis (AA) model is produced by injecting Freund’s 
complete adjuvant into susceptible strains of rats resulting in a T cell-mediated autoimmune 
arthritis. In contrast, the collagen-induced arthritis (CIA) model is produced in some strains of 
mice by immunization with an emulsion of complete Freund's adjuvant and type II collagen 
(CII), resulting in autoimmune arthritis. In the work presented in this thesis, we have used a 
novel mouse model of RA, the collagen antibody-induced arthritis (CAIA) model. The CAIA 
model is produced by injecting a cocktail of monoclonal antibodies targeted against type II 
collagen followed by lipopolysaccharide (LPS) immunization (Nandakumar & Holmdahl, 
2007). With this model, the local joint pathology resembles that observed in RA patients, and 
there is a robust development of pain-like behaviors in these mice (Bas et al., 2012). There are 
several important advantages of the CAIA model comparing to others. The mice in the CAIA 
model is usually in good overall health. There is a shortened disease duration as it bypasses the 
natural development of anti-collagen antibodies.  The CAIA can also be generated in many 
strains of mice that are resistant in other models (Nandakumar & Holmdahl, 2007). 
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1.4 ANALGESICS IN NEUROPATHIC AND INFLAMMATORY PAIN  
Although multimodal treatments are often used to manage pain in the clinics, such as analgesics, 
physical therapy and psychotherapy. The clinical management of pain still relies largely on the 
use of analgesics of different classes. Neuropathic pain is often shown to be resistant to 
available pharmacological agents. The non-steroidal anti-inflammatory drugs (NSAIDs), being 
the most commonly used pain medicines in the world, have no significant effect in neuropathic 
pain. Opiates, the ultimate strong analgesic, have limited effects against neuropathic pain in 
patients (Arner & Meyerson, 1988) while also producing significant side effects, such as 
respiratory depression and constipation.  Long term administration of opiates is known to be 
associated with the development of tolerance, dependence and abuse. 
The first line of analgesics prescribed today to treat neuropathic pain is gabapentin and 
pregabalin (Attal et al., 2010). They are structurally related to the neurotransmitter gamma-
aminobutyric acid (GABA), but effects of these two drugs are not mediated by the GABAergic 
system. It is generally believe that a significant part of their action is mediated by an interaction 
with the α2δ subunit of the voltage-dependent L-type calcium channel in the CNS, thereby 
suppressing neuronal excitability and decreasing the release of neurotransmitters. The 
approved clinical indication for gabapentin and/or pregabalin in neuropathic pain include 
diabetic neuropathy, post-herpetic neuralgia, central pain and fibromyalgia. However, it is 
worth noting that these drugs can only achieve partial relief of neuropathic pain in a not too 
large proportion of patients (Gordh et al., 2008; Serpell, 2002).  
Another class of analgesics that has been suggested to be useful in neuropathic pain are 
antagonists of the NMDA receptors, particularly those of non-competitive and low affinity 
nature such as the over-the-counter antitussive dextromethorphan (Hao & Xu, 1996). However, 
despite positive results from a large number of preclinical studies, there is still a lack of 
convincing clinical evidence for analgesic effect of this type of drugs in neuropathic pain(Aiyer 
et al., 2018). 
Chronic RA pain is also known to be difficult to manage. As at present, there is no cure for RA, 
most treatments can only alleviate symptoms, prevent further joint damage, restore muscle 
capacity and increase the mobility of the RA patients. Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs) such as diclofenac acid or cyclooxygenase-2 inhibitors (COX-2 inhibitors) can be 
used to alleviate pain, swelling and stiffness caused by rheumatoid arthritis. However, the 
effectiveness of these drugs in chronic and severe RA pain is questionable (Andersson et al., 
2013; Steiman et al., 2013; Taylor et al., 2010). Depending on the severity and progression of 
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the disease, today’s doctors often applied disease-modifying anti-rheumatic drugs (DMARDs) 
such as methotrexate, sulphasalazine, and leflunomide (Lee, 2013). However, these drugs do 
not provide adequate pain relive against chronic pain in the RA patients (Andersson et al., 
2013). In addition, because of significant side effects, most drugs of this type are not suitable 
for large doses or long-term use (Andersson et al., 2013; Lee, 2013; Whittle et al., 2012). 
1.5 SINOMENINE 
Sinomenine is an alkaloid (Fig. 1) isolated from the root of Sinomenium acutum (It is a 
climbing plant native to China and Japan, known as Fang-ji or Qing-teng in Chinese. The entire 
Sinomenium acutum plant has been used as traditional Chinese medicine to treat rheumatoid 
arthritis, arrhythmia and neuralgia (Yamasaki, 1976). The usage of sinomenine as a medicine 
was first recorded in a 16th century book called Ben-Cao-Gang-Mu (Compendium of Materia 
Medica). Structurally, sinomenine is a morphine derivative and related to dextromethorphan 
(Plesan et al., 1998). 
 
Fig1. Chemical structure of sinomenine 
1.5.1 Sinomenine and pain 
Our laboratory and others have reported in recent years that sinomenine has board-spectrum 
analgesic effect to relieve nociceptive, inflammatory and neuropathic pain in rodent models 
(Gao et al., 2013a). It has been reported that long-term pretreatment with sinomenine reduces 
the analgesic tolerance to morphine (Wang et al., 2008). In addition, sinomenine could 
significantly decrease the level of 5-HT, dopamine(DA), DOPAC, 5-HIAA, noradrenaline 
content in striatal extracellular fluid in neuropathic pain rat model induced by sciatic nerve 
ligation (Zhang et al., 2013). 
In collagen induced arthritis (CIA) mice, treatment with sinomenine decreased the incidence 
and severity of disease (Feng et al., 2007). In comparison with NSAIDs, sinomenine 
significantly improve rheumatoid factor in patients,  especially against morning stiffness, 
painful joints and erythrocyte sedimentation rate (Xu et al., 2008). Clinical studies also 
  7 
demonstrated that sinomenine administered by subcutaneous injection or oral administration 
was effective in relieving pain in acute and chronic rheumatoid arthritis (Yamasaki, 1976). 
1.5.2 The immunoregulatory effect of sinomenine 
Sinomenine has distinct immunoregulatory function involving histamine, pro-inflammatory 
cytokines, COX2 dependent prostaglandin E2, INF-γ, reactive oxygen species (ROS), NO and 
the activity of NF-κB, p38MAPK and metalloproteinases (MMPs) (Huang et al., 2017; Yang 
et al., 2016; Yuan et al., 2018).  Tumor necrosis factor (TNF) is a cytokine involved in systemic 
inflammation and is a member of a group of cytokines that involved in the development of 
chronic pain. Sinomenine can effectively reduce the TNF level in activated microglia and 
microphages (Huang et al., 2008; Liu et al., 1994). Sinomenine can also suppress the generation 
of COX2 / PGE2, i.e. it can reduce synthesis of PGE2 by lipopolysaccharide (LPS) treated 
macrophages both in vitro and in vivo (Liu et al., 1994).  In enriched microglia, Sub-picomolar 
concentrations of Sinomenine significantly inhibited PGE2 production and COX-2 mRNA 
expression (Qian et al., 2007).  
In CIA mice, treatment with sinomenine reduces the levels of anti-CII and IgG and suppresses 
the antigen–specific splenocyte proliferation (Huang et al., 2007). In addition, Sinomenine 
inhibits transforming growth factor beta (TGF-β) or IL-1β induced proliferation of synovial 
fibroblasts in rats with experimental arthritis and reduces the expression of IL-2 receptor (Liu 
et al., 1996). Sinomenine also inhibit the proliferation of human CD4+T cell (Cheng et al., 
2009) and murine macrophages RAW 264.7 by inducing apoptosis in a dose and time-
dependent manner through activation of ERK (He et al., 2005). Finally, sinomenine inhibits 
lymphocytes proliferation and antibody production by B-cells (He et al., 2005). The potent 
anti-inflammatory and neuroprotective effect of sinomenine is thought to be mediated through 
inhibition of microglial nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-
generated superoxide (Qian et al., 2007). These immunoregulatory properties of sinomenine 
may account for its efficacy in treating RA. In a microarray study, sinomenine was found to be 
able to suppress expressions of 17 genes including IL-6, IL-13, IFITMI, TNFRII, TNF-A, PIGF, 
Daxx, and HSP27 in IL-1β activated T cells (Li et al., 2006). 
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2 AIMS OF THE STUDY 
The present thesis project is built on the initial finding of the analgesic effect of sinomenine 
and has the following specific aims:    
1. To study the development of tolerance to the anti-nociceptive effect of long term 
application of sinomenine in rodent models of neuropathic pain. 
2. To evaluate analgesic effect of sinomenine against experimental arthritic pain in mice 
following acute and chronic administration. 
3. To study synergistic interactions between sinomenine and gabapentin in treating 
neuropathic pain in rodent models. 
4. To compare such interaction with the effect of NMDA receptor antagonists and 
gabapentin in treating neruopathic pain. 
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3 MATERIALS AND METHODS 
3.1 ANIMALS 
The animal experiments that have been used in the studies presented in this thesis were 
conducted with the aim to model different clinical pain conditions. We have strictly followed 
the IASP ethical guidelines and all the experiments were approved by the local animal research 
ethics committee in Stockholm. All mice (C57BL/6 mice, male, Charles River, Sollentuna, 
Sweden; CBA mice, female, Harlan, Horst, The Netherlands) and rats (Sprague-Dawley rats, 
female, Harlan, Horst, The Netherlands; Möllegård, Denmark) were housed 6 or 4 per cage, 
respectively, and in standard laboratory condition (22℃ 12 hours’ light/dark cycle) with ad 
libitum access to water and food. 
3.2 NERVE INJURY ANIMAL MODELS 
3.2.1 Photo-chemically induced sciatic nerve injury in mice and rats 
Pervious papers have described the methods of producing sciatic nerve ischemic injury mice 
and rats model (Hao et al., 2000a; Kupers et al., 1998). Firstly, 75 mg/kg ketamine with 1 
mg/kg medetomidine were used to anaesthetize animals. Then, the photosensitizing dye 
erythrosine B (Red N°3, Aldrich-Chemie, Steinheim, Germany) at dosage of 32.5 mg/kg was 
injected from intravenous. After that, left sciatic nerve was exposed and irradiated using an 
argon ion laser (514 nm, 160 mW, Innova model 70, Coherent Laser Product Division, Palo 
Alto, CA, USA) 45s for mice or 2 min for rats. A heating pad was used to keep the animals’ 
body temperature between 37-38℃ during the period of the irradiation. After the irradiation, 
surgical incision was carefully sutured layer by layer and animals were returned and cared in 
their home cage. 
3.2.2 Photo-chemically induced spinal cord injury in rats 
Pervious paper has described the methods of producing spinal cord injury rat model from our 
lab (Hao et al., 1992). Firstly, 75 mg/kg ketamine with 1 mg/kg medetomidine were used to 
anaesthetize rats. Then, a midline incision was made over T12-L1 vertebral segments. After 
i.v. injection via tail vein of erythrosine B at dosage of 32.5mg/kg, rats were irradiated with an 
argon ion laser for 10 min on the vertebral segments T12-T13. The i.v. injection of dye was 
repeated once after 5 minutes of irradiation. A heating pad was used to keep body temperature 
of rats between 37-38℃ during the period of the irradiation. After the irradiation, surgical 
incision was carefully sutured layer by layer and animals were returned and cared in their home 
cage. 
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3.3 INFLAMMATORY PAIN MODEL 
3.3.1 Collagen antibody induced arthritis model (CAIA) 
CBA female mice (Harlan, Horst, Netherlands) were used in the study. The arthritis was 
induced by i.v. injection of 5 monoclonal Collagen type II antibodies cocktail (0.15ml, 
Chondrex, USA) on day 0. Lipopolysaccharide (LPS, 35 μg, Sigma) was administered by 
intraperitoneal (i.p.) injection on day 5 (Bas et al., 2012; Khachigian, 2006). After the antibody 
injection, inflammation appeared from day 6 and resolved after day 33. The control groups 
were injected with either saline or only with LPS did not show any signs of inflammation. 
Compare to the widely-used Collagen-induced arthritis (CIA) model (Brand et al., 2007), 
CAIA model has more rapid and synchronized onset time of joint inflammation which was 
similar with the pathogenesis of RA in the clinic. 
3.4 BEHAVIOR ASSESSMENT 
3.4.1 Paw withdrawal threshold to mechanical stimulation in sciatic nerve 
injury mice and rats 
The withdrawal threshold of hind paw to mechanical stimulation was tested using a set of 
calibrated von Frey hairs (Stoelting, IL, USA). To test the sensitivity of mechanical stimulation, 
mice or rats were place in plastic cages with a metal mesh floor. After 30 min to 1hour 
habituation, the plantar surface of the hind paws was stimulated with increasing force (from 
0.02g to 4g for mice and 0.02g to 10g for rats) until the animal withdrew the limb. The 
application of each monofilament last 1-2 seconds and was 5 times in total and threshold was 
determined when the animal withdrew the paw at least 3 out of 5 consecutive stimuli. 
3.4.2 Measurement of spread mechanical allodynia in spinal cord injury rats 
Vocalization thresholds to measured mechanical stimulation were tested with a set of von Frey 
hairs (Stoelting, Chicago, IL, USA) in rats. To perform the test, firstly, rats were restrained in 
a standing position on the table gently. Then, the Von Frey hair was pushed onto the skin until 
the filament became bent. The skin area was in dermatomes rostral to the irradiated spinal 
segment-the upper or lower back. The frequency of stimulation was about 1 time per second. 
In each intensity of Von Frey hair, the stimuli were applied 5 to10 times. Pain threshold was 
considered as intensity of Von Frey hair which induced consistent vocalization (>75% response 
rate). The cut-off values was 100g.  
The response of rats to brushing stimulation was tested by using blunt pencil which gently 
stroked the skin on the trunk in a rostro-caudal direction. The frequency of the brush stimuli 
was about 1 time per second and responses were graded with a score as follows: 0 = no 
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observable response (usually normal rats exhibited no reaction); 1 = transient vocalization and 
moderate effort to avoid stimuli; 2 = consistent vocalization and aversive reactions and 3 = 
sustained and prolonged vocalization and aggressive behaviors.  
3.4.3 Measurement of mechanical hypersensitivity and arthritis scoring in 
CAIA mice 
The Paw withdrawal threshold of the ipsilateral hind paw to mechanical stimulation was tested 
by using a set of von Frey hairs (Stoelting, IL, USA). The method of testing was similar to that 
used in the sciatic nerve injury mice. Up-down method (Chaplan et al., 1994) was used to 
calculate the force that cause the 50% probability of paw withdrawal  in CAIA mice. The cut-
off value was 4 g.  For measuring spread mechanical hypersensitivity in CAIA model, the mice 
were gently restrained in a standing position on the table. The von Frey hairs were pushed onto 
skin of flanks and upper back areas until the filament became bent. The frequency of 
stimulation was about 1/s, and in each intensity of von Frey hair, the stimuli were applied 5 
to10 times. The intensity of von Frey hair which induced consistent avoiding or offensive 
behaviors (>60% respond rate) was considered as paw withdrawal threshold. The cut-off value 
was 100g on the flank and upper back areas. 
The arthritis score was used to present the development of join inflammation in the fore and 
hind paws. The evaluation method was visual inspection as described previously (Nandakumar 
et al., 2003). The evaluation was scored every three days after antibody cocktail injection. The 
scoring was based on the inflamed joints’ number. 1 point was given for each inflamed toe or 
knuckle, 5 points were given for each inflamed ankle or wrist, the maximum arthritis score for 
each paw was 15 points and for each mouse was 60 points. 
3.4.4 Measurement of cold hypersensitivity in rats and mice 
Ethyl chloride spray (Rönnings Europa AB, Sweden) was used to exam the responses to cold 
hypersensitivity in rats. The cold hypersensitivity response was graded with a score as follows: 
0 = no observable response; 1 = localized response (skin twitch and contraction), no 
vocalization; 2 = transient vocalization, moderate struggle and 3 = sustained vocalization and 
aggression. Normal rats usually had response score of 0 or 1. Acetone was used to examine the 
cold responses which gently applied onto the plantar surface of the hind paws in mice. The 
response was graded with a score as follows: 0 = no responses; 1 = startle response without 
paw withdrawal, 2 =withdraw of the stimulated hind paw, 3 = sustained withdraw of hind paw 
combined with flitching and licking and/or vocalization. 
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Recently, a quantitative testing of responsiveness to cold sensitivity in spinal cord injury rats 
was developed (Gao et al., 2013b). A Peltier thermode was applied to provide cooling stimuli 
to the flank area. A liquid cooling, hand held Peltier thermode (active surface: 25mm×50mm, 
control resolution: >0.02 ◦C, calibration uncertainty: ±0.2 ◦C) was connected with Modular 
Sensory Analyzer Thermal Stimulator (Somedic, Sweden). The starting temperature was from 
32 ℃ and temperature changing rate was 0.5 ℃ per second. Rats were held in a standing 
position. Then the Peltier thermode was gently pressed onto the shaved flank area. Three 
cooling stimuli were applied and gap between each stimuli was a least 1 min. The average 
temperature when the rats vocalized and withdrew were considered as cold response threshold. 
Cut-off temperature value was 6 ℃. 
3.4.5 Open field test for motor deficits 
Motor deficits were evaluated by using a combined neurological score tests including motor 
score (observed in an open field), righting reflex and extension withdrawal (Hao et al., 1996). 
Total travel distance and rearing numbers of rats and mice were also recorded during the open 
field observation. The neurological score for evaluation of motor function was graded as 
follows:
 
3.5 DRUGS 
Sinomenine was obtained from the National Institute for Food and Drug Control (Beijing, 
China, purity > 99%). It was dissolved in DMSO (Sigma-Aldrich) by the volume rate 1:4. The 
solution was then added with Cremophor EL oil (Sigma-Aldrich) using the volume rate of 1:5. 
Vortex mixer (Bibby Scientific, UK) was used to mix the solution. Any further dilution was 
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made with saline. Gabapentin, dextromethorphan and MK-801 were obtained from Research 
Biochem Inc (Natick, MA, USA) and were dissolved in saline. For single dose administration, 
drugs was apply via oral administration (p.o.) or subcutaneous injection (s.c.) in mice and 
intraperitoneal injection (i.p.) in rats. For repeated administration, drugs was applied twice per 
day at 10AM and 16PM for 5days. For drug combination administration, different drugs were 
injected separately into different body parts to avoid blend.  
3.6 STATISTICS 
All the experiments were double-blind experiments. Data were presented as mean ± standard 
error of mean (SEM) or median ± median absolute deviation (MAD). The data were analyzed 
following paired t-test, Wilcoxon Signed rank test, Mann-Whitney U test or analysis of 
variance (ANOVA) with repeated measures followed by Fisher's Least Significant Difference 
(LSD). All data and figures were presented by Prism (GraphPad Software) and statistics were 
made by SPSS (IBM software), P<0.05 was considered to be statistically significant. 
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4 RESULT 
4.1 REPEATED SINOMENINE ADMINISTRATION ALLEVIATES CHRONIC 
NEUROPATHIC PAIN-LIKE BEHAVIOURS IN RODENTS WITHOUT 
PRODUCING TOLERANCE (PAPER I) 
4.1.1 Repeated administration of sinomenine alleviates pain-like behaviors 
in spinally injured rats 
Rats developed chronic hypersensitivity to mechanical (von-Frey hair and brush) and cold 
stimulation after spinal cord injury. Saline as single or repeated injections has no effect on both 
mechanical and cold hypersensitivity (Fig 1A, 2A, 3A, Paper I). A single dose of i.p. 
administration of sinomenine at 10 or 20 mg/kg also had no analgesic effects on responses to 
mechanical or cold stimulation in SCI rats (Figs. 1-3, Paper I). This is similar as being reported 
in previous study (Gao et al., 2013a). On the other hand, repeated administration of sinomenine 
twice per day at 10 mg/kg increased vocalization threshold to mechanical stimulations and 
reduced response score to brushing from day 2 to day 5 of treatment (Fig 1B, 2B, Paper I).  
Repeated administration of sinomenine twice per day at 10 mg/kg had no effect on cold 
hypersensitivity (Fig 1 C, Paper I).  
Twice a day repeated administration of sinomenine at 20 mg/kg markedly reduced mechanical 
hypersensitivity (Fig.1 C, Paper I) and brushing (Fig.2 C, Paper I) from day 2 to day 5 during 
repeated administration. Moreover, pre-treatment vocalization threshold to mechanical stimuli 
was significantly increased from day 2 (Fig.1 C, Paper I) which remained significantly elevated 
at least another 4 days after suspension of sinomenine administration (Fig.1C, Paper I). The 
pre-treatment brush score was also significantly decreased from day 4 to day 6 after sinomenine 
administration (Fig. 2C, Paper I). Repeated sinomenine at 20mg /kg did not effect on cold 
hypersensitivity (Fig.3 C, Paper I). 
Repeated administration of sinomenine at 40mg/kg twice a day could effectively alleviates 
mechanical hypersensitivity to stimuli with von Frey hair and brushing (Fig.1 D, Fig.2 D, Paper 
I). Pre-treatment vocalization threshold was significantly increased from day 2 to day 9, which 
is again 4 days after the last sinomenine injection (Fig.1 D, Paper I). The vocalization threshold 
retuned pre-treatment baseline on day 12, 7 days after termination of injection (Fig.1 D, Paper 
I). The hypersensitivity to brush stimuli was also reversed on days 2, 4 and 5 by repeated 
sinomenine application (Fig.2 D, Paper I). The threshold of cold temperature was significantly 
decreased on day 1 and 2, and pre-treatment cold was significantly decreased compared to 
baseline level from day 2 to day 9 (Fig.3 D, Paper I), indicating a reduction in cold allodynia 
at this dose. 
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4.1.2 Repeated administration of sinomenine sciatic nerve injury in mice. 
Saline had no effect on paw withdraw threshold (Fig.4 A, Paper I) or cold response (Fig.4 C, 
Paper I). Repeated administration of sinomenine orally at 80 mg/kg twice a day for 5 days in 
mice could significantly increase paw withdraw threshold from day 1 to day 5 (Fig. 4 B, 
Paper I) and reduced cold hypersensitivity (Fig. 4D, Paper I). The baseline of paw withdrawal 
threshold before drug administration was also significantly increased from day 2 to day 12, 
therefore maintaining for 7 days after the last drug application (Fig.4 B, Paper I). 
4.1.3 Other behavioral effects of sinomenine 
We did not observe any significant motor or other behavioral effects of sinomenine at these 
doses following single or repeated administration. There are no withdrawal symptoms in rats 
or mice following the termination of chronic sinomenine administration, including irritation, 
hypersensitivity or decrease in body weight, suggesting that sinomenine did not produce 
physical dependence.   
4.2 SINOMENINE ALLEVIATES MECHANICAL HYPERSENSITIVITY IN MICE 
WITH EXPERIMENTALLY INDUCED RHEUMATOID ARTHRITIS (PAPER II) 
4.2.1 The effect of sinomenine against mechanical hypersensitivity of the 
hind paw  
CAIA mice developed mechanical hypersensitivity of the hind paw in association with the 
development of joint inflammation, both at the acute inflammatory phase (days 11-19 after CII 
antibody injection) and at the post inflammatory phase (days 35-54 after CII antibody injection). 
During the acute and post- inflammatory phase of CAIA mice, sinomenine dose-dependently 
reduced mechanical hypersensitivity in the hind paws via subcutaneous injection for up to 3 
hours after drug administration (Fig.1 A, B, Paper II). The effects were significant at doses of 
40 or 80 mg/kg.  
4.2.2 The effect of sinomenine against spread mechanical hypersensitivity 
In addition to localized hypersensitivity at the hind paw, a spread mechanical hypersensitivity 
could also observed at the neck and flanks areas in CAIA mice at both acute-inflammatory and 
post-inflammatory phase. Sinomenine dose-dependently alleviate the spread mechanical 
hypersensitivity during the first 3–4 hours after drug administration with effective doses of 40 
or 80 mg/kg (Fig.2 A&B, Paper II). 
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4.2.3 No side effects were observed following single-dose sinomenine administration 
In order to investigate the potential side effects produced by single-dose sinomenine 
administration, we applied open field test among three groups of mice: naive mice group, naive 
mice injected with saline (1h before test), and naive mice injected with 80 mg/kg sinomenine 
(1h before test). Duration of passivity, moving distance, rearing time and rectal temperature 
were observed during this experiment.  
There were no significant changes of the passivity duration which indicated no obvious 
allergy or sedation after sinomenine application (Fig.3 A, Paper II). In addition, locomotor 
activities quantified by passed grid numbers and rearing time (Fig.3 B & C, Paper II) were 
also not significantly changed after sinomenine administration. Furthermore, rectal 
temperature was also not significantly changed after sinomenine treatment compared to naive 
or saline treatment group, suggesting that there was no severe allergy (Fig.3 D, Paper II). 
4.2.4 Effect of repeated administration of sinomenine 
During acute-inflammatory phase (days 11–15 after CII antibody injection), repeated 
sinomenine administration twice a day at dose of 80 mg/kg for 5 days, had no significant 
effect to alleviate the arthritis scores in comparison to saline treated CAIA mice (Fig.4 A, 
Paper II). After peak-inflammatory phase, the arthritis scores was slowly dissipated in the 
mice from day 30 to day 54. During post-inflammatory phase (days 49–53), repeated 
sinomenine administration twice a day at 80mg/kg for 5 days had no effect on the arthritis 
scores (Fig.4 A, Paper II). 
During the peak of inflammation (days 11-15 after CII antibody administration), repeated 
administration of sinomenine at 80 mg/kg twice a day last for 5 days significantly alleviate 
the localized mechanical hypersensitivities in the hind paws (Fig.4 B, Paper II) and the spread 
mechanical hypersensitivity in back and neck regions (Fig. 4 C, Paper II) compared to 
corresponding pre-drug baseline on each day. After start of repeated sinomenine application, 
the baseline of mechanical hypersensitivity was significantly increased from day 2 and 
remained significantly for another 3 days after the suspension of drug application (Fig. 4B, 
C, Paper II). 
During the post-inflammatory phase (days 49-53 after CII antibody administration), repeated 
sinomenine administration at 80 mg/kg twice a day significantly alleviated localized and 
spread mechanical hypersensitivity on the hind paws (Fig.4 B, Paper II). After start of 
repeated sinomenine application, the baseline of mechanical hypersensitivity of hind paw 
  19 
was significantly increased from day 2, but baseline of spread hypersensitivity significantly 
increased only from day 5 (Fig.4 B, C, Paper II). The analgesic effect persisted for another 
day after the suspension of drug application. The experiments were terminated on day 54 
according to a pre-determined schedule (Fig. 4 B, C, Paper II). No side effects were recorded 
both on acute inflammatory and post-inflammatory phases during repeated drug application. 
4.3 SYNERGISTIC INTERACTION BETWEEN SINOMENINE AND GABAPENTIN 
IN TREAT-ING NEUROPATHIC PAIN (PAPER III) 
4.3.1 Synergistic analgesia effect of sinomenine and gabapentin in a mouse 
model of peripheral nerve injury. 
The response of paw-withdraw threshold was monitored up to 240 min and tested in every 30-
60 mins after single or combination of drug administration (Fig. 1A, Paper III). A single dose 
of p.o. administration of sinomenine at 20 mg/kg has no significant effect to mechanical 
stimulation in mice with sciatic nerve injury. A single dose of i.p. administration gabapentin at 
30 mg/kg has also no significant effect.  
In low dose combination, when gabapentin was first injected at dosage of 7.5mg/kg, with 
sinomenine administrated at dosage of 10 mg/kg 30-60 min later, no analgesic effect was 
observed up to 4 hours (Fig. 1B, paper III). However, when sinomenine was applied first and 
then gabapentin was administrated 30-60 min later, there different combinations produced 
significant analgesic effect up to 3 hours (Fig. 1C, paper III). These dosages of combination 
were: sinomenine 10mg/kg + gabapentin 7.5mg/kg, sinomenine 20mg/kg + gabapentin 
7.5mg/kg and sinomenine 20mg/kg + gabapentin 15mg/kg (Fig. 1C, paper III). No side effect 
was observed in all combination groups at these dosages. Further, the synergistic interaction 
effect was dose-dependent.  
4.3.2 Synergistic analgesia effect of sinomenine and gabapentin in rats with 
spinal cord injury. 
The experiments were applied 4-5 weeks after spinal cord ischemic injury in rats, the analgesic 
index is vocalization threshold to mechanical stimulation (grams) or cold scores to cold 
stimulation. A single dose administration of sinomenine at 20 mg/kg or gabapentin at 30mg/kg 
did not produce significant analgesia effect against mechanical or cold stimulation in SCI rats 
(Fig. 2A and 2B, Paper III).  
In contrast, when applied in combination, sinomenine and gabapentin by produced marked 
antiallodynic effects in spinally injured rats. There were three dosages of combination tested in 
the experiment: sinomenine 5mg/kg + gabapentin 2mg/kg, sinomenine 10mg/kg + gabapentin 
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4mg/kg and sinomenine 20mg/kg + gabapentin 7.5mg/kg. All with sinomenine pretreated 30-
60 min before gabapentin. Further, the synergistic interaction effect was dose-dependent with 
higher dose combination producing larger and longer effect (Fig. 2C and 2D, Paper III). 
Similarly, simultaneous administration of 10mg/kg sinomenine and 4mg/kg gabapentin could 
also produce significant synergistic analgesia effect to against mechanical hypersensitivity and 
cold allodynia (Fig. 3A and 3B, Paper III). No side effect was observed in all drug combination 
groups. 
4.3.3 Synergistic analgesia effect of repeated administration of sinomenine 
and gabapentin in rats with spinal cord injury. 
Repeated combination injection of 10mg/kg i.p. sinomenine + 4mg/kg i.p. gabapentin 
twice/day were used to study the analgesic effect of chronic administration of the drug 
combination in SCI rats. In two rounds of experiments, this combination were applied twice 
daily (10AM and 16PM) for 7days and 14 days. Sinomenine was applied 30-60 min before 
gabapentin with dosing interval of 6 hours per day. The analgesic index is vocalization 
threshold to mechanical stimulation (grams). The repeated combination produced significant 
analgesic effect against mechanical stimulation. More importantly, during the chronic 
administration, the pain threshold before the administration was also significantly increased, 
which indicates that the drug combination produced a sustained effect. Two days after 
termination of last drug administration, the pain threshold of rats returned to pre-treatment level 
(Fig. 4, Paper III). No observable side effect in rats were produced during repeated 
administration. 
4.4 GABAPENTIN AND NMDA RECEPTOR ANTAGONISTS INTERACTS 
SYNERGISTICALLY TO ALLEVIATE ALLODYNIA IN TWO RAT MODELS 
OF NEUROPATHIC PAIN (PAPER IV) 
4.4.1 Synergistic analgesia effect in spinal cord injury rats 
In spinally injured rats with mechanical and cold hypersensitivity, we examined the effects of 
combination of gabapentin and two NMDA receptor antagonists. Single dose i.p. 
administration of dextromethorphan at 20 mg/kg or gabapentin at 30 mg/kg did not alleviate 
allodynia (Fig. 1-3, Paper IV). Increasing the dosage of dextromethorphan or gabapentin 
produce side effect, including sedation and motor impairment for gabapentin and hyperactivity 
for dextromethorphan. In contrast, the low dosage combination gabapentin with 
dextromethorphan: gabapentin 7.5mg/kg + dextromethorphan 5mg/kg, gabapentin 15mg/kg + 
dextromethorphan 10mg/kg,  and gabapentin 30mg/kg + dextromethorphan 10mg/kg 
significantly increased the vocalization threshold to von-Frey stimulation (Fig. 1, Paper IV), 
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reduced and normalized brushing score (Fig. 2, Paper IV) or cold score(Fig.3, Paper IV). The 
synergistic effect of dextromethorphan and gabapentin is long lasting, but reversible. No side 
effect was observed, such as sedation, motor impairments or hyperactivity at these 
combinations at low doses.  
Similarly, i.p. administration MK-801 at dosage of 0.05 or 0.1 mg/kg did not affect mechanical 
allodynia-like behavior in SCI rats. In contrast, the low dosage combination of MK-801 (0.01 
or 0.05 mg/kg) together with 15 mg/kg gabapentin could significantly increase vocalization 
threshold to von-Frey stimulation (Fig. 4, Paper IV). 
4.4.2 Synergistic analgesia effect in sciatic nerve injury rats 
Sciatic nerve injury rats developed mechanical hypersensitivity of hind paw after irradiation  
after 1-2 weeks. Single dose of i.p. administated dextormethorphan at 4 0mg/kg or gabapentin 
at 100 mg/kg did not affect paw withdrawal threshold in SNI rats despite the presence of side 
effects (Fig. 5, Paper IV). In contrast, the combination of 30mg/kg gabapentin with 20 mg/kg 
dextromethorphan significantly increased paw withdrawal threshold to mechanical  stimuli 
in rats with sciatic nerve injury (Fig. 5, Paper IV). No side effect was observed in this 
combination. 
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5 DISCUSSION 
5.1 REPEATED SINOMENINE ADMINISTRATION ALLEVIATES CHRONIC 
NEUROPATHIC PAIN WITHOUT TOLERANCE 
Previous studies by others and us showed that sinomenine exhibited antinociceptive effect in a 
wide range of rat and mice models (Gao et al., 2013a; Gao et al., 2014; Rao et al., 2017; Zhu 
et al., 2016; Zhu et al., 2014). Work presented in this thesis expanded these results by showing 
that repeated administration of sinomenine produced persistent effects in rat and mice models 
of neuropathic pain with signs of tolerance. Pre-drug response threshold was significantly 
increased after two injections, which also maintained for some days after the termination of 
drug administration. Similar to our previous results in both rats and mice (Gao et al., 2013a), 
sinomenine seems has less effect to against cold allodynia than mechanical hypersensitivity. 
Importantly, during or after repeated administration of sinomenine, there were no side effects 
such as sedation, motor impairment or irritation was observed. Previous study has shown that 
daily administration of sinomenine at dosage of 40 or 80 mg/kg in rats for two weeks did not 
influence growth, appetite and blood pressure (Hson-Mou Chang, 1986). No withdrawal 
symptoms were observed after the termination of repeated sinomenine application. These 
results suggest that sinomenine has great potential to treat chronic neuropathic pain with low 
tolerance and abuse. 
Repeated administration of sinomenine produced similarly effect on neuropathic pain-like 
behaviors in our models compare to the anti-epileptics lacosamide and gabapentin previously 
studied in our laboratory (Hao et al., 2006; Hao et al., 2000b; Wu et al., 2004). Repeated 
administration of gabapentin could increase analgesic effect compare to the doses that were 
ineffective as a single injection (Hao et al., 2000b). Similarly, repeated lacosamide increased 
pre-drug baseline responses (Hao et al., 2006). On the other hand, systemic morphine 
application could not alleviate allodynia in SCI rat models. Intrathecal morphine application 
could have some effect to anti the allodynia, but tolerance was rapidly observed on the second 
day after drug application(Yu et al., 1997). 
One major effect of sinomenine in our SCI rats and SNI mice models is that it reduced pre-
drug baseline hypersensitivity following repeated administration. Sinomenine has a relatively 
short half-life in rat plasma (Liu et al., 1996).  It is therefore unlikely that this effect against 
baseline hypersensitivity following repeated injections is due to an accumulation of the drug. 
The metabolites of sinomenine are known to be present in at least three forms (Cheng et al., 
2007). However, it is unclear whether these metabolites are pharmacologically active or has 
antinociceptive effect. It is likely that the effects of repeated sinomenine administration reflect 
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sustained physiological changes resulting from repeated drug treatment. Such changes are, 
however, reversible since pain recurred within days following the last dose of sinomenine.  
The mechanism of action for the effect of sinomenine in models of neuropathic pain is not clear. 
It is not mediated by the opioid pathway through the µ-receptor since naloxone (opioid receptor 
antagonist) could not reverse anti-allodynic effect of sinomenine (Gao et al., 2013a) and the 
profile of analgesia produced by sinomenine is different from that of systemic morphine (Bulka 
et al., 2002; Yamasaki, 1976).  Interestingly, the effect of sinomenine is similar to a non-opioid 
antitussive dextromethorphan, which is also a weak noncompetitive NMDA receptor 
antagonist (Hao & Xu, 1996). One possible mechanism for the effect of sinomenine may be 
related to its ability to modulate neurotransmitter release in the central nervous system. 
Sinomenine upon systemic injection affects the level of monoamines in extracellular fluid in 
the striatum in rats with sciatic nerve injury, raising the level of noradrenaline while decreasing 
in level of dopamine and serotonin. These effects have been shown to be correlated with 
analgesic effect (Zhang et al., 2013). Chronic nerve injury may produce long lasting effects on 
transmitter synthesis and neuronal functions which may be altered by sinomenine. In addition, 
sinomenine also has distinct immunoregulatory properties, reducing the production of 
cyclooxygenase (COX)-2 dependent prostaglandin E2 (PGE2) (Liu et al., 1994), as well as 
reduce nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and p38 
mitogen-activated protein kinases (p38MAPK) signal pathways (Huang et al., 2008; Wang et 
al., 2005). Sinomenine also has neuroprotective effect, decreasing the production of superoxide 
ions through inhibiting the microglial NADPH oxidase (Qian et al., 2007).  Finally, previous 
studies have shown that some of the effects of sinomenine may be mediated through GABAA 
receptor (Zhu et al., 2014) or the acid-sensing ion channel and calcium channels (Wu et al., 
2011). Any or some of these effects may reduce neuronal sensitization contributing to the effect 
of sinomenine against neuropathic pain.  
5.2 THE EFFECT OF SINOMENINE ON EXPERIMENTAL RHEUMATOID 
ARTHRITIS  
Sinomenine has long been used in China and Japan as an anti-rheumatic drug (Yamasaki, 1976). 
The efficacy of sinomenine against RA is well established in rodent RA models (Huang et al., 
2007; Liu et al., 1996) and clinically, sinomenine has been shown in some studies to be more 
effective than NSAIDs in ameliorating morning stiffness, painful joints and erythrocyte 
sedimentation rate (Xu et al., 2008). Sinomenine reduces the production of proinflammatory 
cytokines by suppressing the activation of NF-κB (Cheng et al., 2009; Wang et al., 2005; Zhou 
et al., 2008). Sinomenine also reduces the increase of inflammatory mediators such as TNF and 
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IL1-β following inflammation (Wang et al., 2005). These mechanisms may contribute to the 
effect of sinomenine against RA.  
In study II, repeated sinomenine administration twice per day for 5 days could not alter arthritic 
scores in the CAIA mice at the acute-inflammatory phase, which means that in our CAIA 
model, sinomenine did not have a direct effect against the disease progression of RA. This is 
likely to due to the model used. The CAIA model, by directly injecting anti-CII arthritogenic 
antibody cocktail to trigger arthritis, bypasses step of T-cell activation as required in the CIA 
model. Thus, the anti-rheumatic effect reported in the previous animal studies may suggest that 
the effect of sinomenine may be due to inhibition of T-cell activation. Nonetheless, single or 
repeated administration of sinomenine effectively and dose-dependently alleviated the 
localized and spread mechanical hypersensitivity during both acute- and post-inflammatory 
phases without producing side effects. Thus, it is likely that the analgesic mechanism of 
sinomenine is independent from possible anti-inflammatory action of the compound in RA and 
our results also suggest that some of clinical efficacy of sinomenine may in fact be due to its 
analgesic effect.  No tolerance was observed by repeated administration of sinomenine to the 
analgesic effect, which was similar to neuropathic pain models (Gao et al., 2014).  
The effect of sinomenine against pain-like behaviors in the CAIA model may be due to multiple 
factors. It has been shown previously there is a marked activation of microglia in the spinal 
cord of CAIA mice in comparison to control mice (Bas et al. 2012). Sinomenine can interact 
with neuro-immune crosstalk by suppressing microglia activation (Qian et al., 2007; Shukla & 
Sharma, 2011) which may be the primarily mechanism explaining the effect of sinomenine in 
the CAIA model.  However, sinomenine produced a range of other pharmacological effects in 
the nervous system which may also be involved in the analgesic mechanisms in arthritic pain. 
These effects may include previously mentioned immunoregulative properties and actions on 
systems such as histamine, proinflammatory cytokines, COX2 dependent PGE2, interferon 
gamma (INF-γ), reactive oxygen species (ROS), nitric oxide (NO), NF-κB, p38MAPK, 
metalloproteinases (MMPs) and TNF. Further studies of the effects of sinomenine on neuronal 
and immune systems may lead to better understanding of the mechanisms of analgesia by 
sinomenine in mice model of RA. 
5.3 SYNERGISTIC INTERACTION BETWEEN SINOMENINE AND 
GABAPENTIN IN TREATING NEUROPATHIC PAIN 
The management of chronic pain is one of the most important health issues with limited options 
today. In the present study, we showed that combined administration of small doses of 
sinomenine and gabapentin produced marked synergistic interaction in rodent models of 
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neuropathic pain, far superior than each drug administered alone. Thus, in rodent models of 
neuropathic pain, adequate pain reduction could only be observed with the dosages at 100 
mg/kg for gabapentin (Hao et al., 2000b) and 40 mg/kg (Gao et al., 2013a) for sinomenine, 
doses of drugs that are already producing some side effects. When two drugs were combined 
however, much less doses of gabapentin and sinomenine, can have strong anti-nociceptive 
effect without producing side effects, indicating that gabapentin and sinomenine can 
dramatically potentiate each other's analgesic efficacy in combination. Further, repeated 
administration of the combination of sinomenine and gabapentin also produced significant 
effect, increasing the baseline threshold before drug administration, with no observable side 
effects and tolerance. These findings raise the feasibility of using the combination of 
sinomenine and gabapentin as a novel therapy in neuropathic pain. 
There are several possible mechanisms through which that sinomenine and gabapentin act 
synergistically to reduce neuropathic pain. Both compounds are able to modulate and/or 
partially block calcium channels (Striano & Striano, 2008; Wu et al., 2011) and there are some 
evidence that they both enhance GABAergic neural inhibition (Kuzniecky et al., 2002; Zhu et 
al., 2014). There are also evidences that morphine and dextromethorphan can potentiate the 
effect of gabapentin on chronic pain in the clinic (Gilron et al., 2005). In the last study of this 
thesis, we showed that this is also the case for dextromethorphan and gabapentin in our 
experimental model of neuropathic pain. The structure of sinomenine is related to morphine 
and dextromethorphan (Yamasaki, 1976), it is tempting to suggest that some of the effect of 
sinomenine may be mediated through pathways related to the effect of dextromethorphan.. 
Finally, it is worth noting that time appears to be an important factor when it comes to combined 
drug administration of sinomenine and gabapentin. Thus, the best effect is obtained when 
sinomenine was pretreated 30-60 min before gabapentin. The reason for this is unclear, maybe 
metabolic in nature or related to the neuronal actions of these compounds. 
5.4 GABAPENTIN AND NMDA RECEPTOR ANTAGONISTS INTERACTS 
SYNERGISTICALLY TO ALLEVIATE PAIN-LIKE BEHAVIORS IN TWO RAT 
MODELS OF NEUROPATHIC PAIN 
In a fashion very similar to sinomenine, the work presented in the last paper of this thesis 
showed that combining NMDA receptor antagonists, parimarily dextromethorpahn and 
gabapentin produced synergistic effect aginst pain-like behaviors in the rat models of 
neuropathic pain after spinal cord or sciatic nerve injury. The effect of the combination is again 
synergistic rather than additive in comparison to previous studies with using either drugs alone 
(Hao & Xu, 1996; Xu et al., 2001). At effective doses, the combination did not produce 
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increased side effects. The mechanisms by which synergism between dextromethorphan and 
gabapentin occurs are unclear. As mentioned above, the analgesic effect of gabapentin may be 
related to its interaction to the 2 subunit of the voltage-dependent calcium channels (VDCCs) 
(Gee et al., 1996; Rose & Kam, 2002). Thus, such synergism may be derived from a reduction 
in calcium entry through simultaneous blockade of VDCCs and NMDA receptor/channels. It 
is interesting to note therefore  that gabapentin per se often produced limited effect on various 
types of Ca2+ currents (Fink et al., 2000; Martin et al., 2002; Rock et al., 1993; Stefani et al., 
1998). Such interaction may also occur directly at the NMDA receptor complex. The anti-
hyperalgesic effect of gabapentin was blocked by D-serine which is an agonist at the glycine 
site of the NMDA receptor (Jun & Yaksh, 1998; Singh et al., 1996). Gabapentin is also able to 
reduce the release of glutamate that may also contribute to its interaction with NMDA receptor 
antaognists (Dooley et al., 2000; Maneuf et al., 2001). Since MK-801 also enhances the effect 
of gabapentin, it is unlikely that such interaction take place solely at the VDCCs.  
The synergism between dextromethorphan and gabapentin appears to be larger in spinally 
injured rats than in rats with sciatic nerve injury. This is similar to our previous results that both 
drugs are less potent in the periphery vs. central model (Hao & Xu, 1996; Hao et al., 2000b). 
This suggest that the combination of dextromethorphan and gabapentin may be particularly 
useful in treating spinal cord injury pain which is a difficult clinical problem (Yezierski, 2002). 
In support, one earlier clinical study has shown that combination of dextromethorphan and 
gabapentin alleviated neuropathic pain in patients with spinal cord injury (Sang, 2002). 
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6 CONCLUSIONS 
1. The anti-allodynic effect of sinomenine upon repeated chronic administration enhanced its 
effect without tolerance in two rodents model of neuropathic pain. No side effects can be 
observed from the persistent, reversible analgesia. 
2. Sinomenine is effective in alleviating localized and spread hypersensitivities in CAIA mice 
both during acute inflammation and in postinflammatory phase. Repeated administration 
of sinomenine has increasd the pre-drug baseline threshold to mechanical stimuli without 
producing tolerance. The results in paper I and II may suggest potential clinical application 
of sinomenine as a novel analgesic in chronic neuropathic and arthritic pain management. 
3. The combined therapy of sinomenine and gabapentin has promising synergic effect in 
alleviating neuropathic pain with less dosage and reduced side effects. The repeated 
administration of combined therapy also produced significant analgesic effect without 
introducing tolerance. 
4. The combined therapy of NMDA receptor antagonists and gabapentin could provide 
synergic effect alleviating neuropathic pain with increased efficacy and reduced side 
effects. This study, together with paper III, indicate that compared to single agent, the 
combined therapy entails benefits including improved analgesic effectiveness and reduced 
adverse effects with smaller doses of individual drugs. Sinominine may have similar 
analgesic mechanism with NMDA receptor antagonists. However, such drug composition 
and the application criteria need to be further validated in clinical studies before it can be 
widely used. 
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a b s t r a c t
Background and aims: We have previously reported that systemic administration of sinomenine pro-
duced antinociception in various experimental pain conditions in rodents, particularly in models of
neuropathic pain. In the present study we assessed the effects of repeated administration of sinomenine
in two rodent models of neuropathic pain in order to study the development of tolerance.
Methods: The analgesic effect of sinomenine was tested in female Sprague-Dawley rats that exhibited
mechanical and cold hypersensitivity following ischaemic injury to the spinal cord and in male C57/BL6
mice that developed mechanical hypersensitivity after ischaemic injury to the sciatic nerve. Briefly, the
animals were anaesthetized and injected i.v. with the photosensitizing dye erythrosine B. Vertebral seg-
ments T12 to T13 in rats or the sciatic nerve in mice were exposed and irradiated under an argon ion
laser for 10min or 45 s, respectively. In rats, mechanical hypersensitivity to pressure with von Frey hairs,
the response to brushing and decreasing cold temperature were tested in the flanks or upper back areas.
In mice, mechanical hypersensitivity on the hind paw to von Frey hairs and response to cold following a
drop of acetone were measured. Sinomenine was administered i.p. in rats and p.o. in mice at 10:00 and
16:00, twice a day for 5 days. Response threshold before and 2h after drug administration at 10.00h was
recorded.
Results: Repeated administration of sinomenine at 10 or 20mg/kg twice a day, doses that have no anal-
gesic effect as single injection, alleviated mechanical, but not cold allodynia in spinally injured rats and
the effect was maintained during the 5 day treatment period with no signs of tolerance. Furthermore,
the pre-drug response threshold was significantly elevated during repeated treatment with 20mg/kg
sinomenine. Sinomenine administered at 40mg/kg twice a day for 5 days significantly reduced mechan-
ical and cold alldoynia, elevated pre-drug response threshold without tolerance development in spinally
injured rats. Similarly, sinomenine at 80mg/kg twice a day for 5 days significantly reduced mechanical
allodynia in mice with sciatic nerve injury and increased pre-drug response threshold with no sign of
tolerance. The effect of sinomenine on response threshold persisted for days after termination of the 5
day drug administration.
Conclusions: The results suggest that repeated administration of simomenine produced an enhanced
anti-allodynic effect without tolerance in rodent models of neuropathic pain.
Implications: Sinomenine may be tested as a novel analgesic in treating some forms of chronic neuro-
pathic pain in patients.
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1. Introduction
In the European Union the prevalence of chronic pain is around
20% in adults and imposes a huge burden on society [1]. Chronic
neuropathic pain that occurs after injury or disease in the central
or peripheral nervous systemcauses a great reduction of life quality
in patients [2]. However, the lack of adequate treatments of neuro-
pathic pain remains problematic. The first line drugs used to treat
neuropathic pain, such as pregabalin or gabapentin, only produce
partial pain relief in a subset of patients [3–5]. Opioid analgesics
are ineffective against neuropathic pain in the majority of patients
and are often associated with side effects including constipation,
tolerance and drug abuse [6,7].
Traditional Chinese medicines (TCM) are widely used for man-
agement of various clinical pain conditions in China and may
harbour a rich source of potential drug candidates, which West-
ern drug companies are turning towith ever increasing urgency [8].
Sinomenine is amorphinederivative alkaloidpurified fromthe root
of the climbing plant Sinomenium Acutum. Sinomenine is tradi-
tionally used as a remedy for rheumatism and arthritis (RA) in Asia.
Clinical research indicated that comparedwithNSAIDs, sinomenine
wasmore effective in amelioratingmorning stiffness, painful joints
anderythrocyte sedimentation rate inRApatients [9]. In addition to
possible pain relieving effect in RA, sinomenine has been suggested
to be effective in some types of neuralgia, such as sciatic neuritis
and lumbalgia, based mostly on anecdotal evidence [10].
In searching for effective components in TCMs for treating
chronic pain, we have recently studied the effect of sinomenine in
models of acute and chronic pain in rodents. Sinomenine appears
to be particularly effective against neuropathic pain after injury
to both the peripheral and central nervous system. In the present
study, we evaluated the analgesic effect of sinomenine upon
repeated administration on neuropathic pain using two rodent
models, photochemically-induced spinal cord injury in rats [12],
and sciatic nerve injury in mice [13].
2. Methodology
2.1. Animals
All experiments were approved by the regional research ethics
committee. We used female Sprague-Dawley rats (Harlan, Horst,
The Netherlands) weighing 300–350g, and male C57BL/6 mice,
(Charles River, Sollentuna, Sweden)weighing 25–30g. The rats and
mice were housed 4 or 6 per cage respectively at a constant room
temperature of 22 ◦C in a 12:12h light–dark cycle with ad libitum
access to food and water.
2.2. Photochemically-induced spinal cord injury in rats
The method of producing photochemically induced spinal
cord ischaemic injury in rats has been described in detail pre-
viously [12]. Briefly, the rats were anesthetized with 75mg/kg
ketamine+1mg/kg medetomidine and a midline incision was
made in the skin overlying vertebral segments T12-L1. Following
i.v. injection of 32.5mg/kg of the photosensitizing dye erythrosine
B (Sigma-Aldrich), vertebral segment T12 or T13 (spinal segments
L3-5) was irradiated with an argon ion laser (Coherent) for 10min.
A second dose of erythrosin B was injected 5min after the start of
irradiation. During irradiation, the temperature of the animals was
maintained 37–38 ◦C.
2.3. Behavioural tests in rats
The threshold to mechanical stimulation was tested by gently
restraining the animals in a standing position and calibrated von
Frey hairs (Stoelting, Chicago, IL, USA) were applied to the shaved
flanks or upper back areas. The von Frey hairs were applied 5–10
times at each intensity, with the frequency of 1/s. The stimulus
which induced consistent vocalization (to >75% of stimuli) was
considered as vocalization threshold. The cut-off value was 100g.
For examining the response to brush stimuli, the skin on the
flanks was briskly stroked with the point of a pencil in a rostral to
caudal direction [14]. The response of the animals was graded with
a score of 0 =no response, 1 =moderate efforts to avoid the probe
but no vocalization, 2 = clear avoiding behaviour to the stimulus
with transient vocalization, and 3=vigorous efforts to avoid the
stimulus, sustained vocalization in response to the probe.
Cooling stimuliwereappliedwithaPeltier thermode to theflank
[15]. A fluid cooled, hand held Peltier thermode (active surface:
25mm×50mm, control resolution: >0.02 ◦C, calibration uncer-
tainty: ±0.2 ◦C) connected to a Modular Sensory Analyzer Thermal
Stimulator (Somedic, Sweden) was used. The baseline tempera-
ture was 32 ◦C and the rate of temperature change was 0.5 ◦C/s.
Rats were held gently in a standing position and the thermode was
pressed against the shaved flank area. Three cooling stimuli were
applied at 1min intervals and the average temperature at which
the rats vocalized was taken as cold response threshold with 6 ◦C
as cut-off temperature.
2.4. Photochemically induced sciatic nerve injury in mice
The detailed method for producing ischaemic injury to the sci-
atic nerve in mice has been described previously [13]. Briefly,
the animals were anaesthetized with 75mg/kg ketamine+1mg/kg
medetomidine and the left sciatic nerve was exposed. After i.v.
injection of 32.5mg/kg erythrosine B the sciatic nerve was irra-
diated under an argon ion laser for 45 s.
2.5. Behavioural test in mice
Thewithdrawal thresholdof the ipsilateral hindpawtomechan-
ical stimulation after sciatic nerve injury was tested using a set of
calibrated von Fray hairs as described above. The response to cold
after nerve injury was tested using a drop of acetone applied to
the plantar surface of the hind paw ipsilateral to the nerve injury.
The immediate response after acetone application was observed
andscoredas follows:0 =no responses;1 = startle responsewithout
evident paw withdrawal, 2 =withdraw of the stimulated hind paw,
3= sustained withdraw of the simulated hind paw with flitching or
licking.
2.6. Drugs
For preparation of sinomenine (obtained from The National
Institute for Food and Drug Control, Beijing, China) for injection it
was first dissolved with DMSO (Sigma-Aldrich), then mixed with
Cremophor EL oil (Sigma-Aldrich) and saline by a vortex mixer
(Bibby Scientific, UK) using the volume rate of 1:4:5. Any fur-
ther dilution was made with saline. Sinomenine was administered
i.p. in rats and orally in mice. To perform oral administration, the
mouse was held in an upright standing position and a bulb tipped
gastric gavage needle was used to deliver the sinomenine solu-
tion into the stomach by the attached syringe. Sinomenine was
administered twice daily for 5 days at 10:00h and 16:00h. Baseline
sensitivity to mechanical and cold stimuli was assessed before the
administration of sinomenine at 10:00h and two hours later, when
sinomenine’s effectwasmaximal [11]. Control groupsof spinal cord
injured rats andsciaticnerve injuredmicewereadministeredsaline
twice a day for 5 days.
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2.7. Statistics
The experiments were conducted blindly wherever a con-
trol group was included. Data are presented as mean± SEM or
median±MAD, andwere analyzed by ANOVAwith repeatedmeas-
ures and the Kruskal–Wallis test followed by Bonferroni/Dunn post
hoc test, Wilcoxon signed rank test, or paired t-test. P<0.05 is con-
sidered to be statistically significant.
3. Results
3.1. Effect of repeated administration of sinomenine on pain-like
behaviours in spinally injured rats
As previously reported, rats developed chronic hypersensitivity
to mechanical (von Frey hair and brushing) and cold stimuli after
spinal cord injury [16,17]. The pharmacological experiments were
conducted at 8 weeks following injury when hypersensitivity was
maximal and stable.
Saline had no effect on either mechanical (Figs. 1A and 2A)
or cold (3A) sensitivity. A single dose of i.p. sinomenine at 10 or
20mg/kg had no effects on responses to mechanical or cold stimu-
lation inSCI rats (Figs. 1B–D,2B–Dand3B–D)aspreviously reported
[11]. In contrast, repeated administration of 10mg/kg sinomenine
twice per day elevated vocalization threshold to mechanical stim-
ulations and reduced response score to brushing from day 2 to
day 5 of treatment (Figs. 1B and 2B). However, repeated 10mg/kg
sinomenine had no effect on hypersensitivity to cold (Fig. 3B).
Repeated administration of sinomenine at 20mg/kg reduced
mechanical hypersensitivity to stimulationwith von Frey hairs and
brushing from day 2 to day 5 (Figs. 1C and 2C). Furthermore, pre-
drug response threshold tovonFreyhairswas significantly elevated
from day 2 of sinomenine treatment and the threshold remained
significantly elevated compared to day 1 for at least 4 days after the
cessation of drug application (Fig. 1C). The pretreatment response
score to brushing was also significantly decreased from day 4 to
day 6 after the start of drug treatment (Fig. 2C). However, 20mg/kg
sinomenine did not alleviate allodynia to cooling (Fig. 3C).
Sinomenine administered twice/day at 40mg/kg effectively
reduced mechanical hypersensitivity. Baseline thresholds to stim-
ulation with von Frey hairs was significantly increased from day 2
of treatment and lasted until day 9, 4 days after the last adminis-
tration of sinomenine (Fig. 1D). The response threshold returned
to pre-sinomenine baseline level on day 12 (Fig. 1D). Hypersensi-
tivity to brushing was also reversed on days 2, 4 and 5 following
repeated sinomenine (Fig. 2D). The threshold temperature for cold
stimulation was significantly decreased (indicating a decrease in
coldhypersensitivity) 2hafter sinomenineduring thefirst twodays
(Fig. 3D). The pre-drug cold response temperaturewas significantly
reduced from baseline level from day 2 to day 9 (Fig. 3D), again
suggesting a sustained reduction in cold hypersensitivity.
In general, sinomenine dose-dependently suppressed hyper-
sensitivity tomechanical (Fig. 1) and cold (Fig. 3) in rats after spinal
cord injury.
3.2. Effect of repeated sinomenine on neuropathic pain-like
behaviours in mice following sciatic nerve injury
Saline had no effect on paw withdrawal thershold (Fig. 4A) or
cold (Fig. 4C). Sinomenine at 80mg/kg administeredp.o. twice aday
for 5daysproduced significantly increasedpawwithdrawal thresh-
old on days 1–5 (Fig. 4B). Therewas also a significant and persistent
elevation in pre-drug baseline response threshold to simulation
with von Frey hairs from day 2 and was maintained for 7 days
after the termination of drug treatment (Fig. 4B). Sinomenine also
significantly reduced mechanical and cold post-drug responses, in
comparison with the pre-drug thresholds (Fig. 4B and D).
4. Discussion
We have previously reported that a single dose of sinome-
nine alleviated pain-like responses in spinal cord injured rats at
or above 40mg/kg [11]. In the present study we showed that
repeated administration of sinomenine even at 10mg/kg reduced
mechanical allodynia-like responses in spinal cord injured rats after
the third injection and the effect was maintained during the 5
day treatment with no signs of tolerance. Repeated administra-
tion of sinomenine at 20 or 40mg/kg not only reduced mechanical
allodynia-like responses without tolerance, but also significantly
increased pre-drug baseline response threshold after two injec-
tions. The increase inpre-drug response thresholds for the response
to brush were maintained during the 5 day administration of
sinonemine at 10 or 40mg/kg doses and maintained up to day 6
following the last 20mg/kg dose.
Similar effects were observed in a mouse model of neuropathic
pain after sciatic nerve injury in which 80mg/kg sinomenine, an
effective dose on its own [11], produced marked anti-allodynic
response against mechanical stimulation after repeated injections
for 5dayswithoutproducing tolerance. Furthermore, as in ratswith
spinal cord injury, we observed a significant increase in pre-drug
response threshold after two injections which was maintained to
day 12, 7 days after the termination of drug administration. In both
rats and mice, sinomenine appears to be less effective against cold
than mechanical hypersensitivity, which is similar to our previous
results [11].
We found that a single i.p. administration of sinomenine at
20 and 40mg/kg produced little or no side effects, and 80mg/kg
simonemine caused some sedation in rats [11]. In the present
study no side effects (sedation, motor impairment or irritation)
wereobservedduringor after repeated sinomenineadministration.
Previous studies in rats have also suggested that daily administra-
tion at 40 or 80mg/kg for two weeks did not influence growth,
appetite and blood pressure [18]. There were also no apparent
withdrawal symptoms following the terminationof drug treatment
in the present study. These observations, together with the fact
that no tolerance to the anti-allodynic effects of sinomenine was
observed after repeated administration, suggest that sinomenine
may be useful to treat chronic neuropathic pain.
The effects of repeated sinomenine on neuropathic pain-
like behaviours in our models are similar to the effect of the
anti-epileptics lacosamide and gabapentin [19–21]. In particular,
the analgesic effect of gabapentin was also increased following
repeated administration at doses that were ineffective as a single
injection [19]. Moreover, repeated lacosamide alleviated pre-drug
baseline responses, similar to that of sinomenine [20]. In contrast,
i.p. morphine did not alleviate allodynia in rats with spinal cord
injury. Intrathecal morphine did have some anti-allodynic effect,
but tolerance was observed after 2 days of twice daily treatment
[22].
One of the remarkable effects of sinomenine in these two rodent
models of neuropathic pain is that it reduced baseline hypersen-
sitivity following repeated administration, resulting in persistent
reduction in allodynia. Since sinomenine has a relatively short
half-life in rat plasma [23,24], it is unlikely that this effect is
due to an accumulation of the drug following repeated injections.
Some of the anti-allodynic effects of sinomenine may be medi-
ated by its metabolites which are known to be present in at least
three forms [25]. However, it is unknown whether these metabo-
lites are pharmacologically active. Alternatively, the effects of
repeated sinomenine may reflect sustained physiological changes
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Fig. 1. Effect of i.p. saline (A), or 10mg/mg (B), 20mg/kg (C) and 40mg/kg (D) sinomenine, administered twice a day for 5 days on vocalization threshold to stimulation with
von Frey hairs, on the flanks of in rats with spinal cord injury. N=6–12 in each group and data are presented as median±MAD. A two-way ANOVA with repeated measures
and the Kruskal–Wallis test indicated significant overall differences (P<0.01) in groups with different doses of sinomenine or saline (A–D). The Bonferroni/Dunn’s post hoc
test revealed that pre- and 2h post-drug responses were significantly different (P<0.01) in the groups administered 20mg/kg (C) and 40mg/kg (D) sinonemine. Furthermore,
they also had significantly higher (P<0.01) pre- and post-drug thresholds than the groups who received saline (A) or 10mg/kg sinomenine (B). Pre- and post-drug responses
were compared on each day using the Wilcoxon signed rank test (B–D) and significant differences are shown as #=P<0.05 and ##=P<0.01. Pre-drug vocalization threshold
on day 1 was compared with pre-drug thresholds following drug administration with the Wilcoxon signed rank test (C and D) and * =P<0.05.
Fig. 2. Effect of i.p. saline (A) or 10mg/mg (B), 20mg/kg (C) and 40mg/kg (D) sinomenine, administered twice a day for 5 days on brush score on the flanks of rats with spinal
cord injury. N=6–8 in each group and data are presented as median±MAD. A two-way ANOVA with repeated measures and the Kruskal–Wallis test indicated significant
overall differences (P<0.01) in groups with different doses of sinomenine or saline (A–D). The Bonferroni/Dunn’s post hoc test revealed that pre- and 2h post drug responses
were significantly different (P<0.01) in the groups administered 10mg/kg (B), 20mg/kg (C) and 40mg/kg (D) sinonemine. Furthermore, they also had significantly higher
(P<0.01) pre- and post-drug thresholds than the groups who received saline (A). Pre- and post-drug responses were compared on each day using the Wilcoxon signed rank
test and significant differences are shown as #=P<0.05. Pre-drug brush score on day 1 was compared with pre-drug scores following drug administration with the Wilcoxon
signed rank test (B–D) and * =P<0.05.
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Fig. 3. Effect of i.p. saline (A) or 10mg/mg (B), 20mg/kg (C) and 40mg/kg (D) sinomenine, administered twice a day for 5 days on the cold response in rats with spinal
cord injury. N=6 in each group and data are presented as mean± SEM. Two way ANOVA with repeated measures and the Kruskal–Wallis test indicated significant overall
differences (P<0.05) in groups receiving different doses of sinomenine or saline (A–D). The Bonferroni/Dunn’s post hoc test revealed that pre- and 2hpost-drug cold responses
were significantly different (P<0.05) only in the group receiving 40mg/kg sinonemine. Pre- and post-drug cold responses were compared on each day using the paired t-test
and a significant difference was found in the 40mg/kg group (D), #=P<0.05. The pre-drug cold response on day 1 was compared with pre-drug thresholds following drug
administration with the paired t-test (C and D), *P=<0.05.
Fig. 4. Effect of p.o. saline (A and C) or 80mg/kg sinomenine (B and D) administered twice a day for 5 days on the withdrawal threshold to stimulation with von Frey hairs (A
and B) and cold score to stimulation with acetone (C and D) in mice with sciatic nerve injury. N=6 animals per group. Data are presented as median±MAD. Two-way ANOVA
with repeated measures and the Kruskal–Wallis test indicated a significant overall group difference (P<0.01) in mechanical (A and B) and cold (C and D) hypersensitivities.
The Bonferroni/Dunn’s post hoc test revealed that pre- and 2h post-drug cold responses were significantly different (P<0.01) in the group receiving 80mg/kg sinomenine (A
and C) but not saline (B andD). Pre- and post-drugwithdrawal threshold (B) and cold score (D)were compared on each day using theWilcoxon signed rank test and significant
differences are shown as #=P<0.05. The pre-drug withdrawal threshold and cold score on day 1 were compared with pre-drug responses following drug administration
with the Wilcoxon signed rank test and *P=<0.05 (B).
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resulting from repeated drug treatment. Such changes are, how-
ever, reversible and may require continuous drug treatment
since allodynia recurred within days following the last dose of
sinenomine.
The mechanisms for the anti-allodynic effect of sinomenine
in models of neuropathic pain are not clear. We have previ-
ously shown that the anti-allodynic effect of sinomenine was not
reversed by the opioid receptor antagonist naloxone [11] and the
profile of analgesia produced by sinomenine is different from that
of systemic morphine [22,26]. In contrast, the effect profile of
sinomenine is similar to that of dextromethorphan, a non-opioid
antitussive that is an weak noncompetitive NMDA receptor antag-
onist [11,27]. Sinomenine is structurally related to levorphanol and
dextromethorphan and is also antitussive [18]. Although there is
currently no evidence that sinomenine can function as an NMDA
receptor antagonist, it does have a neuroprotective effect possi-
bly mediated by blocking of acid-sensing ion channel and calcium
channels [28]. Furthermore, repeated administration of sinome-
nine delays tolerance to morphine [29,30], which is also observed
with dextromethorphan [31].
One of the possible mechanisms for the anti-allodynic effect
of chronic sinomenine may be related to its ability to modulate
neurotransmitter release in the spinal cord and brain. Systemic
sinomenine alters the level of monoamines in extracellular fluid
in the striatum in rats after sciatic nerve injury with increase in
the level of noradrenaline and decrease in level of dopamine and
serotonin [32]. These effects are correlated with analgesic effect
of sinomenine [32]. Chronic sinomenine may produce long term
effects on transmitter synthesis and neuronal functions through
altered transmitter release.
Sinomenine also has distinct immunoregulatory and neuropro-
tectiveproperties. It can reduce theproductionofCOX-2dependent
Prostaglandin E2 [33], block NF-B and p38MAPK signal path-
ways [34,35], and reduce microglia activation by inhibiting NADPH
oxidase [36]. It is conceivable that some of these properties of
sinomenine may reduce neuronal sensitization in the peripheral
and central nervous system and contribute to its analgesic effects
in neuropathic pain.
5. Conclusion
In conclusion, thepresent results showed that the anti-allodynic
effect of sinomenine upon repeated chronic administration did not
lead to tolerance, but rather enhanced its effect, in two rodentmod-
els of neuropathic pain, resulting in a persistent, but reversible,
analgesia with no observable side effects.
6. Implications
The results from this research may suggest potential clinical
application of sinomenine as a novel analgesic in treating chronic
neuropathic pain.
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Background  and aims:  We  have  previously  reported  that  sinomenine,  an alkaloid  isolated  from  the  root
of  the  plant  Sinomenium  acutum,  had  antinociceptive  effect  in  rodent  models  of  acute  inflammatory  or
neuropathic  pain.  As  a  traditional  medicine,  sinomenine  is  used  in  China  to treat  rheumatoid  arthritis
(RA).
Methods:  In the  present  study,  we  evaluated  the  potential  antinociceptive  effect  of  sinomenine  in a
mouse  model  of RA,  collagen  type  II antibody  (CII  Ab)  induced  arthritis  (CAIA) after  acute  and  chronic
administration.
Results:  As single  administration,  sinomenine  at 40 or 80  mg/kg  significantly  reduced  mechanical  hyper-
sensitivity  both  at the  time  of peak  joint  inflammation  (days  11–19  after  CII Ab injection)  or  during  the
post-inflammatory  phase  (days  35–54).  No  tolerance  to the  effect  of  80  mg/kg  sinomenine  was  observed
during  repeated  injection  twice  a day  for 5 days  from  day  11 to day  19  or  from  day  49  to  day  53  after  CII
Ab  injection  in  CAIA  mice.
Conclusions:  We  have  shown  that  sinomenine  is  effective  in alleviating  localized  and  spread  hypersensi-
tivities  in  CAIA  mice  both  during  acute  inflammation  and  in  post-inflammatory  phase.  Further,  repeated
sinomenine  administration  has  elevated  the  baseline  mechanical  threshold  without  producing  tolerance.
Implications:  Sinomenine  may  be clinically  useful  to treat chronic  pain  in  RA, including  wide-spread
pain  which  appears  to  be  a  difficult  clinical  problem  despite  the  improvement  in  the acute  treatment  of
RA by  disease  modifying  agents.
© 2014  Scandinavian  Association  for the  Study  of  Pain.  Published  by  Elsevier  B.V.  All  rights  reserved.
1. Introduction
Pain is a major clinical feature of rheumatoid arthritis (RA). Not
only has pain been suggested to be an important patient-reported
DOI of refers to article: http://dx.doi.org/10.1016/j.sjpain.2015.01.002.
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outcome in RA [1,2], but also the severity of pain has strong impact
on the quality of life of patients. Although pain is usually considered
as a marker for inflammation, recent studies have shown that in
many RA patients chronic pain continue to be a major problem
even after the remission of inflammation [2]. Furthermore, many
RA patients also suffer from chronic wide-spread pain in a fashion
similar to fibromyalgia [3].
Non-steroidal anti-inflammatory drugs (NSAIDs) and
acetaminophen are first line pain therapies in RA and weak
opioids are also sometimes used [2]). In both cases, analgesia
http://dx.doi.org/10.1016/j.sjpain.2014.12.003
1877-8860/© 2014 Scandinavian Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
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in a substantial portion of patients remains unsatisfactory and
long-term application of these drugs is limited by side effects
and in the case of opioids, the development of tolerance [4].
Disease-modifying anti-rheumatic drugs such as methotrexate
are known to reduce acute symptoms in RA including pain, but
their efficacy against the development of chronic pain is less clear
[1,3,5].
The root of the climbing plant Qingteng (Sinomenium acutum)
has long been used in East Asia as a remedy for disease condi-
tions similar to rheumatism as recorded in for example the 16th
century book, Bencao Gangmu (Compendium of Materia Medica)
[6]. The major active component in Qingteng has been identified
as sinomenine, a morphinan derivative alkaloid that is struc-
turally similar to dextromethorphan. We  have recently shown that
sinomenine possesses a wide spectrum of analgesic properties
towards different experimental pain conditions in rodents, includ-
ing acute inflammatory pain by carrageenan or neuropathic pain
after peripheral/central nervous system injury [7]. In the present
study, we examined the potential antinociceptive effect of single or
repeated sinomenine administration against experimental arthritic
pain. The collagen antibody induced arthritis (CAIA) model was
used, which is a mouse model of RA based on the injection of a
cocktail of monoclonal antibodies directed against type II colla-
gen followed by immunizing the animals with lipopolysaccharide
(LPS) [8]. In this model the local joint pathology resembles that
observed in RA patients and pain-like responses, mainly mani-
fested as localized and/or spread mechanical hypersensitivity, can
be detected both during the acute inflammatory phase or chronic
post-inflammatory phase [9].
2. Material and methods
2.1. Animals
All experiments were approved and conducted strictly followed
regulations of the regional research ethics committee. Female CBA
mice (Harlan, Horst, The Netherlands), weighing 25–30 g were
used. The animals were housed 6 per cage with a constant room
temperature at 22 ◦C in a 12:12 light–dark cycle and ad libitum
access to food and water.
2.2. CAIA in mice
In CBA mice, as described previously [9], CAIA was induced
by intravenous (i.v.) injection of anti-CII arthritogenic antibody
cocktail (0.15 ml,  Chondrex, USA), which contains 5 monoclonal
antibodies on day 0. Then, immune reaction was  triggered by
intraperitoneal (i.p.) injection of 35 !g LPS, (serotype O55:B5;
Sigma) diluted in 100 !l of physiologic saline on day 5. Inflamma-
tion in the joints was examined and evaluated by visual inspection
after antibody cocktail injection. The scoring was  based on joint
inflammation in each paw, being defined by swelling and redness
[8]. Briefly, each inflamed toe gave one point, an inflamed wrist or
ankle gave five points, resulting in a score of between 0 and 15 for
each paw and between 0 and 60 for each mouse.
2.3. Assessments of mechanical hypersensitivity
Baseline mechanical sensitivity in the hind paw, neck and flank
areas were measured five times at three day intervals before the
collagen antibody injection. Animals with baseline threshold below
50% of the average value were excluded. After collagen type II anti-
body injection, mechanical threshold was tested for 54 days, always
at the same time during the day. For testing of paw withdraw
threshold, the mice were placed in plastic cages with a metal mesh
floor. After habituation for 1 h the plantar surface of the hind paw
was stimulated with a set of calibrated von Fray hairs (Marstock,
Denmark). The up-down method [10] was  used to calculate the
force that caused paw withdrawal in 50% of trials. For testing spread
mechanical hypersensitivity the mice were gently restrained in
a standing position, and the flanks and upper back were stimu-
lated using von Frey hairs (Stoelting, Chicago, IL, USA). Stimuli were
applied 5–10 times at each intensity at 1 s−1. The stimulus which
induced consistent avoiding or offensive behaviours (>60% respond
rate) was  considered as responding threshold. The cut-off value was
4 g on the paws and 100 g on the flanks and back.
2.4. Assessments of side effects
To assess if mice develop motor deficiencies, severe allergy or
sedation after sinomenine application, we performed an open field
test in naïve mice. The open field arena is 50 cm × 50 cm with 25
grids (the area of one grid is 10 cm × 10 cm), in which mice (with-
out any previous experience in the open field test) were allowed
to move freely for 5 min. The total travel distance (quantified by
the number of passed grids), number of rearing behaviours and
duration of passivity (time when animal showed no movement)
were measured. After the open field test, rectal temperature was
monitored by a thermometer (FHC, Bowdoin, ME, USA).
2.5. Drugs
For preparation of injecting solutions, sinomenine (standard
substance was  obtained from The National Institute for Food
and Drug Control, Beijing, China) was first dissolved with
DMSO (Sigma–Aldrich), then mixed with Cremophor EL oil
(Sigma–Aldrich) and saline by a vortex mixer (Bibby Scientific, UK)
using the volume rate of 1:4:5. Any further dilution was made
with saline. Sinonemine was  injected subcutaneously (s.c.), into the
loose skin over the neck. Dose response curves for sinomenine were
acquired in the acute phase (days 11–19 after CII antibody injection)
and chronic phase (days 36–54 after CII antibody injection).
2.6. Statistics
The experiments were conducted blindly. Data were presented
as mean ± SEM, and were analyzed by ANOVA (with or without
repeated measurements) followed by Fisher’s PLSD post hoc test,
Wilcoxon signed rank test, and Mann–Whitney U test. P < 0.05 was
considered to be statistically significant.
3. Result
3.1. The dose-dependent effect of sinomenine against mechanical
hypersensitivity of the hind paw
During the first 3 h after drug administration in the inflam-
matory phase of CAIA (days 11–19 after CII antibody injection), a
single dose of 40 and 80 mg/kg s.c. sinomenine dose-dependently
reduced mechanical hypersensitivity in the hind paws (Fig. 1A). In
the post-inflammatory phase during days 35–54 post CII antibody,
sinomenine also had a similar effect as during peak inflammation
(Fig. 1B).
3.2. The dose-dependent effect of sinomenine against spread
mechanical hypersensitivity
As we  have previously observed, mice subjected to CAIA devel-
oped, in addition to localized mechanical hypersensitivity of the
paws, a spread mechanical hypersensitivity primarily at the neck
and flanks. A single dose of 40 or 80 mg/kg sinomenine also signifi-
cantly alleviated the spread mechanical hypersensitivity during the
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Fig. 1. The effect of saline or various doses of sinomenine injected s.c. on hind paw
withdrawal threshold to mechanical stimulation during acute inflammation (at one
day  during days 11–19, A) and post inflammation (at one day during days 36–54,
B)  in CAIA mice. Arrow indicates drug application which is just prior to behavioural
testing at time 0 h. The threshold at time 0 h represents hyperalgesic value. Increased
threshold represents an attenuated/alleviated hyperalgesia. N = 6–11 mice in each
group. Data are presented as mean ± SEM. ANOVA with repeated measures indi-
cated a significant general difference between the groups (F = 11.70, P < 0.0001 for A,
and F = 14.27, P < 0.0001 for B). Fisher’s PLSD post hoc test indicated that the effect
of sinomenine at 40 or 80 mg/kg is significantly different from the saline group.
*P  < 0.05, **P  < 0.01, post-drug time points were compared with pre-drug baselines
using Wilcoxon signed rank test. #P < 0.05, ##P < 0.01, post-drug time points were
compared with corresponding saline controls using Mann–Whitney U test.
first 3–4 h after drug administration both in the inflammatory and
post-inflammatory phases of CAIA (Fig. 2A and B).
3.3. No side effects were observed following single-dose
sinomenine administration
For detecting potential side effects produce by single-dose
sinomenine, we applied open field test for 5 min in naïve mice and
naïve mice injected with saline or 80 mg/kg sinomenine (1 h prior
to test). There was no increase of the duration of passivity (Fig. 3A),
which is the sign for allergy or sedation, after sinomenine or saline
application. In addition, locomotor activities quantified by number
of passed grids (Fig. 3B) and number of rearing behaviours (Fig. 3C)
were also not changed following sinomenine administration. Fur-
ther, rectal temperature (which can be affected by severe allergy),
was also similar in the sinomenine treated group compared to naïve
or saline treated animals (Fig. 3D).
Fig. 2. The effect of saline or various doses of sinomenine on response threshold to
mechanical stimulation at the neck/flank region during acute inflammation (at one
day during days 11–19, A) and post inflammation (at one day during days 36–54, B) in
CAIA mice. Arrow indicates drug application which is just prior to behavioural test-
ing  at time 0 h. The threshold at time 0 h represents hyperalgesic value. Increased
threshold represent an attenuated/alleviated hyperalgesia. N = 6–11 mice in each
group. Data are presented as mean ± SEM. ANOVA with repeated measures indi-
cated a significant general difference between the groups (F = 7.00, P < 0.01 for A,
and  F = 2.68, P < 0.05 for B). Fisher’s PLSD post hoc test indicated that the effect
of  sinomenine at 40 or 80 mg/kg is significantly different from the saline group.
*P  < 0.05, **P < 0.01, post-drug time points were compared with pre-drug baselines
using Wilcoxon signed rank test (A, B). #P < 0.05, ##P < 0.01, post-drug time points
were compared with corresponding saline controls using Mann–Whitney U test.
3.4. Effect of repeated administration of sinomenine
Repeated injection of 80 mg/kg sinomenine 2 times/day for 5
days during days 11–15 post CII antibody administration (inflam-
matory phase), had no effect on the arthritis scores in the CAIA
model in comparison to saline treated animals (Fig. 3A). During the
post-inflammatory phase, the arthritis in CAIA animals slowly dis-
sipated from day 30 to day 54, repeated sinomenine at days 49–53
had no effect on the arthritis scores (Fig. 3A).
Sinomenine administered 2 times/day for 5 days during the peak
of inflammation significantly alleviated the mechanical hypersen-
sitivities in the hind paws (Fig. 3B) and in the neck/flank region
(Fig. 3C). Baseline mechanical hypersensitivity was  significantly
increased from the second day after the start of repeated sinome-
nine treatment, and remained significantly elevated for 3 days after
the cessation of sinomenine treatment (Fig. 3B and C).
During the post-inflammatory phase, repeated sinomenine
administration (at days 49–53 post CII antibody administration,
80 mg/kg, 2 times/day) significantly alleviated mechanical hyper-
sensitivity both of the hind paws and on the neck/back regions
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Fig. 3. Effect of saline or 80 mg/kg sinomenine on duration of passivity (A), moved distance (B), number of rearing behaviours (C) and rectal temperature (D), in naïve mice
during open field test for 5 min. N = 5–6 mice. Data are presented as mean ± SEM. One-way ANOVA indicated there is no significant difference between groups in (A–D;
P  > 0.05).
(Fig. 3A and B). Baseline mechanical hypersensitivity was  signifi-
cantly increased from the second day after the onset of repeated
sinomenine treatment for the hind paw, but only on day 5 for the
spread hypersensitivity (Fig. 3B and C). The effect persisted for
at least one day after the cessation of sinomenine treatment as
the experiments were terminated on day 54 according to a pre-
determined schedule (Fig. 3B and C).
No side effects were observed during repeated sinomenine
treatments during both the inflammatory and post-inflammatory
phases (Fig. 4).
4. Discussion
As previously observed [9], experimental arthritis using the
CAIA model generated hyperalgesic response (mechanical hyper-
sensitivity to paws) both during the acute inflammatory phase and
during the post-inflammatory phase. Furthermore, in CAIA mice
there is a spread mechanical hypersensitivity in the neck/back
region which can be observed both acutely and post inflammation.
In the present study, we were able to demonstrate that adminis-
tration of sinomenine effectively and dose-dependently alleviated
the localized and spread mechanical hypersensitivity during both
phases without producing side effects such as motor deficiency,
severe allergy or sedation. This supports our previous conclusion
that sinomenine is a novel analgesic with a wide spectrum of
activities against different types of pain [7]. Furthermore, repeated
administration of sinomenine during the peak of inflammation did
not change the arthritic scores, despite producing marked analge-
sia. Thus, it is likely that the analgesic mechanism of sinomenine
is independent from possible anti-inflammatory action of the com-
pound.
Sinomenine is used in China and Japan as an anti-rheumatic
drug [11]. It has been reported that in collagen induced arthritis
(CIA) mice, treatment with sinomenine decreased the incidence
and severity arthritis [12]. Clinical research has also indicated
that compared with NSAIDs, sinomenine was more effective in
ameliorating morning stiffness, painful joints and erythrocyte sed-
imentation rate in RA patients [13]. In the present study, however,
we did not find that repeated sinomenine (2 times/day for 5 days)
reduced acute inflammation (arthritis score) in the CAIA mice.
This could be due to several factors, such as dose, timing of the
treatment and models used. In contrast to the CIA model, which
requires T-cell activation, the CAIA model, by directly injecting
antibodies against the type II collagen to trigger arthritis, bypasses
this step. Thus, the anti-rheumatic effect of sinomenine may be
related to inhibition of T-cell activation. It is also possible that
some of the attribution of sinomenine as an anti-rheumatic may
be derived from its analgesic effect against arthritic pain.
No tolerance was  seen to the analgesic effect of sinomenine
following repeated administration. Rather, there was a significant
increase in pre-drug response threshold which lasted beyond the
duration of drug treatments. Lack of tolerance to the effect of
sinomenine was  similarly noted in rodent models of neuropathic
pain [14]. It has also been shown that long-term pretreatment
with sinomenine may  delay the analgesic tolerance to morphine
[15]. Sinomenine has a relatively short half-life in the plasma of
rodents with no accumulation [16,17]. It is thus unlikely that this
effect of repeated sinomenine administration is due to an accumu-
lation of the drug. The metabolites of sinomenine are present in at
least three forms [18]. It is unclear whether these metabolites are
responsible for the effect of repeated sinomenine since pharmaco-
logical properties of these metabolites are unknown. Finally, the
effects of repeated sinomenine may  reflect lasting, but not perma-
nent, changes in the nervous system resulting from repeated drug
treatment.
The mechanism for the effect of sinomenine in the CAIA model
is not clear. Sinomenine is not an opioid and the antinocicep-
tive effect of sinomenine in neuropathic pain is not mediated by
naloxone sensitive opioid receptors [7]. Sinomenine can interact
with neuro-immune crosstalk by suppressing microglia activation
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Fig. 4. Effect of 80 mg/kg sinomenine injected 2 times/day for 5 days on the development of arthritic scores (A), mechanical hypersensitivity of the hind paw (B) and spread
mechanical hypersensitivity (C) in CAIA mice. N = 6 mice per group. Data presented as mean ± SEM. In (A) there is no significant difference between sinomenine and saline
treated groups in the arthritic scores. In (B and C) sinomenine upon repeated treatment reduced mechanical hypersensitivitiy (#P < 0.05) compared to corresponding pre-drug
value  on each day of the treatment (B, C), and *P < 0.05, compared to the baseline value of days 11 and 49 (starting time of repeated sinomenine treatment) using Wilcoxon
signed rank test.
[19,20], reduce inflammation and hyperactivity in the central ner-
vous system. Previously, microglial activation was found in the
spinal cord of CAIA but not control mice [9], which suggests the
presence of microglia mediated central sensitization in this model.
Thus, it is possible that down-regulation of microglial activities in
the spinal cord by sinomenine can be responsible for the reduction
pain-related behaviour in the CAIA model. Moreover, sinomenine
can modulate the synthesis of factors considered important for RA
induced inflammation and pain, such as TNF, prostaglandin E2,
INF-", reactive oxygen species, NO, NF-#B, p38MAPK and metal-
loproteinases [12,19,21–23]. Suggesting that, it is also conceivable
that the analgesic mechanisms of sinomenine can be mediated by
these factors.
5. Conclusions
In conclusion, the present results have shown that sinomenine
is effective in alleviating localized and spread hypersensitivities
in CAIA mice both during acute inflammation and in post-
inflammatory phase. Further, repeated sinomenine administration
has raised the baseline mechanical threshold without producing
tolerance.
6. Implications
The present results indicate that sinomenine by itself or in com-
bination with other established drugs, may be clinically useful in
14 T. Gao et al. / Scandinavian Journal of Pain 7 (2015) 9–14
management of chronic pain in RA conditions, including wide-
spread pain which appears to be a difficult clinical problem despite
the improvement in the acute treatment of RA by disease modifying
agents.
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Abstract 
Background and aims: Chronic pain is 
one of the biggest unmet clinical challenge, 
involving a broad patient population in the 
world. The management of chronic pain in 
the clinical settings is restricted by the lack 
of effective tools. This study aims to assess 
the efficacy of sinomenine and gabapentin 
in combination for treating peripheral and 
central chronic neuropathic pain using ani-
mal models. 
Methods: The study was conducted in mice 
with photochemically induced sciatic nerve 
injury, and rats with photochemically in-
duced spinal cord injury. Sinomenine was 
applied by oral administration (p.o.) in mice, 
injected subcutaneously (s.c.) in mice and 
intraperitoneally (i.p.) in rats. Gabapentin 
was applied i.p. both in mice and rats. Dif-
ferent treatment schedules were utilized 
regarding the time points of administration 
of the two drugs, and the efficacy of re-
peated treatment was tested in rats with 
effective combination treatment regime. 
The paw withdrawal threshold and the vo-
calization threshold to mechanical 
stimulation were tested in mice and rats re-
spectively, after single and repeated drug 
administration.  
Results: In low dose combination (in which 
each drug alone does not show efficacy) in 
mice with peripheral neuropathic pain, when 
gabapentin was first applied, and si-
nomenine administrated 30-60 min later, no 
analgesic effect was observed. However, 
when sinomenine was applied first and then 
gabapentin was administrated 30-60 min 
later, the combination produced significant 
analgesic effect up to 3 hours. Similarly, in 
rats with spinal cord injury, the drug combi-
nation produced a strong and prolonged 
analgesic effect at the dosages 1/10 of the 
effective dosages of each drug alone. More-
over, the repeated administration of low 
dose combination of sinomenine and 
gabapentin also elevated the baseline 
threshold before drug administration, with 
no notable side effects.  
Conclusions: The combined therapy of si-
nomenine and gabapentin has synergic 
effect in alleviating experimental neuro-
pathic pain after spinal cord and peripheral 
nerve injury in rodent models. The repeated 
administration of combined therapy also 
produced significant effect without produc-
ing tolerance. These findings suggest 
feasibility of applying the combination of si-
nomenine and gabapentin as a novel 
neuropathic pain therapy. 
 Key words 
Sinomenine, Gabapentin, Neuropathic Pain, 
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1. Introduction 
Chronic pain, such as neuropathic pain after 
injuries to the peripheral or central nervous 
systems is one of the biggest unmet clinical 
challenge, involving a broad patient popula-
tion in European Union and the world 
(Geber et al., 2009; Treede et al., 2008). 
Such pain is complex, long-term, resistant 
to treatments, and can significantly de-
crease the quality of life of affiliated patients 
(Breivik et al., 2006; Jensen & Finnerup, 
2007; van Hecke et al., 2014).  
The management of chronic pain in clinical 
settings is restricted by the lack of effective 
tools and the improvement in treatment 
strategy is limited during recent years 
(Beniczky et al., 2005; Jensen & Finnerup, 
2007). Current treatment strategy mainly 
depends on the first-line pharmaceutical 
drugs, such as TCA antidepressants and 
antiepileptic (i.e., gabapentin and pregaba-
lin) medications, however, they do not 
provide adequate pain relief in majority of 
the patients (O'Connor & Dworkin, 2009). 
The latest report has shown that, only 32% 
patients with gabapentin had substantial 
benefit (at least 50% pain relief) and 46% 
had moderate benefit (at least 30% pain re-
lief) in postherpetic neuralgia (Wiffen et al., 
2017). Moreover, the usage of opioid anal-
gesics, as the second-line treatments under 
certain clinical circumstance, are often inef-
fective in long run and are associated with 
side effects including constipation, nausea 
and tolerance (Benyamin et al., 2008; Von 
Korff, 2013). These current challenges ad-
vocate the development of novel methods 
for the treatment of chronic pain with in-
creased analgesic efficacy, minimized side 
effects and no occurrence of drug tolerance. 
Sinomenine is an alkaline substance ex-
tracted from the roots of the plant 
Sinomenium acutum, which has similar 
structure to morphine and dextrome-
thorphan (Yamasaki, 1976). It has long 
been used in East Asia to treat conditions of 
rheumatism. In mouse collagen-induced ar-
thritis (CIA) model, Sinomenine treatment 
can reduce the severity and frequency of ar-
thritis (Huang et al. 2007). Compared with 
non-steroidal anti-inflammatory drugs 
(NSAIDS), sinomenine is superior on morn-
ing stiffness, joint pain and on erythrocyte 
sedimentation rate (Xu et al. 2008). Si-
nomenine is also used as an 
immunosuppressive agent, which inhibits 
lymphocyte proliferation and the synthesis 
of B cell antibodies (He et al. 2005). In our 
previous study, we found that sinomenine 
possessed analgesic properties in treating 
rodents with neuropathic pain after periph-
eral and central nervous system injury, 
without producing observable side effects 
(Gao et al., 2013). In addition, repeatedly 
administered sinomenine resulted no toler-
ance, but on the other hand, increased the 
baseline pain threshold (Gao et al., 2014), 
suggesting it has a promising potential  to 
be applied in chronic pain therapy.  
In clinical practice, it is very common that 
chronic pain patient starts with monotherapy, 
but ends up in using drug combinations. It 
has been shown that the effectiveness of 
combined therapy are improved compared 
with monotherapy in treating neuropathic 
pain (Vorobeychik et al., 2011). The mono-
therapy of gabapentin is commonly used as 
the first-line regimen for management of 
neuropathic pain. Evidence has showed 
 that gabapentin added with morphine can 
achieve better effectiveness in relieving 
neuropathic pain than single agent of each 
drug, at lower dosage (Gilron et al., 2005). 
What is more, our recent study has shown 
that gabapentin and NMDA receptor antag-
onist dextromethorphan can interact 
synergistically to alleviate allodynia in ani-
mal model of neuropathic pain (Shi et al., 
2018). Since sinomenine is structurally re-
lated to morphine and dextromethorphan  
(Yamasaki, 1976), but do not have mor-
phine associated addiction and tolerance, 
assessing the possibility if sinomenine 
could replace morphine to combine with 
gabapentin and obtain an enhanced anal-
gesic effect is of high clinical importance. 
Therefore, this study aims to assess the ef-
ficacy of sinomenine and gabapentin 
combination for treating peripheral and cen-
tral chronic neuropathic pain using our well-
established photochemically induced nerve 
injury animal models, and to determine the 
dosage effect for monotherapy as well as 
combination therapy of these two drugs at 
different application scenarios. 
2. Material and methods 
2.1 Animals 
All the experiments were strictly following 
the IASP ethical guidelines and approved 
by the local animal research ethics commit-
tee. All mice (C57BL/6 mice, male, Charles 
River, Sollentuna, Sweden) were housed 6 
per cage, and rats (Sprague-Dawley rats, 
both sexes, Harlan, Horst, The Netherlands; 
Möllegård, Denmark) were housed 4 per 
cage, both respectively and in standard la-
boratory condition (22 ºC 12 hours’ 
light/dark cycle) with ad libitum access to 
water and food. 
2.2. Photochemically induced sci-
atic nerve injury in mice 
Detailed method for producing sciatic nerve 
ischemic injury in mice has been described 
previously (Hao et al., 2000a). Mice were 
anaesthetized by 75 mg/kg ketamine add 
with 1 mg/kg medetomidine, then the left 
sciatic nerve was exposed from surrounding 
tissue above 1cm to the trifurcation. After 
being injected intravenously (i.v.) with 32.5 
mg/kg of the photosensitizing dye erythro-
sine B (Red N13, Aldrich-Chemie, 
Steinheim, Germany), the sciatic nerve was 
irradiated under an argon ion laser (514 nm, 
0.16W, Innova model 70, Coherent Laser 
Product Division, Palo Alto, CA) for 45 sec-
onds. During the experiment, a heating pad 
was applied to maintain the body tempera-
ture between 37-38 ºC. After irradiation, the 
wound was closed and mice were returned 
to their home cages. 
2.3 Behavioral test in mice 
The paw withdrawal threshold to mechani-
cal stimulation was applied two weeks after 
sciatic nerve injury, when animal exhibited 
mechanical sensitivity of the hind paws. The 
withdrawal threshold of the ipsilateral hind 
paw to mechanical stimulation was tested 
using a set of calibrated von Frey hairs 
(Stoelting, IL, USA). To test the sensitivity of 
mechanical stimulation, mice were place in 
plastic cages with a metal mesh floor. The 
plantar surface of the hind paws was stimu-
lated with increasing force from 0.02g to 4g 
until the animal withdrew the limb. Each fil-
ament was applied 5 times and threshold 
was taken when the animal withdrew the 
paw at least 3 out of 5 consecutive stimuli.  
 2.3. Photochemically induced spi-
nal cord injury in rats 
The method of producing photochemically 
induced spinal cord ischemic injury in rats 
has been described previously (Hao et al., 
1991, 1992). Rats were anaesthetized by 
75 mg/kg ketamine add with 1 mg/kg me-
detomidine. Then a midline incision was 
made in the skin overlying vertebral seg-
ments T12-L1. After i.v. injection of 
erythrosine B (32.5 mg/kg), vertebral seg-
ment T12 or T13 (spinal segments L3–5) 
was irradiated under an argon ion laser for 
10 minutes. A second dosage of erythrosin 
B was applied 5 min after the start of irradi-
ation. During irradiation, the body 
temperature of rats was maintained be-
tween 37–38 ºC. After irradiation, the wound 
was closed in layers and rats are returned 
to their home cages. 
2.4 Behavioral test in rats 
The vocalization threshold were tested 4–5 
weeks after the spinal cord injury when the 
rats exhibited hypersensitivity to innocuous 
mechanical and cold stimuli at flank or up-
per back areas as described previously(Xu 
et al., 1992). The rats were shaved and gen-
tly held in a standing position. A set of von 
Frey hairs was used to produce graded 
pressure to the skin from 0.02g to 100g, 5–
10 times in each pressure with the fre-
quency at 1/s. The stimulation which 
induced consistent vocalization (>75% re-
sponse rate) was considered as 
vocalization threshold.  
The cold score was examined with ethyl 
chloride spray (Rönnings Europa AB, Swe-
den). It was applied onto the shaved flank 
or upper back area to produce cold stimuli. 
The response was graded according to the 
following scale: 0 = no response; 1 = startle-
like response, no vocalization, 2 = vocaliza-
tion, 3 = consistent vocalization combined 
with avoidance. 
2.5 Drugs 
For preparation of injection solution, Si-
nomenine (obtained from the National 
Institute for Food and Drug Control, Beijing, 
China, purity > 99%) was dissolved in 
DMSO (Sigma-Aldrich), then mixed with 
Cremophor EL oil (Sigma-Aldrich) and sa-
line by vortex mixer (Bibby Scientific, UK) 
using the volume rate of 1:4:5. Any further 
dilution was mixed with saline. Sinomenine 
was applied by single oral administration 
(p.o.) or injected subcutaneously (s.c.) into 
the skin over the neck in mice and injected 
intraperitoneal (i.p.) in rats. 
For preparation of injection, gabapentin 
(Research Biochemicals Inc., USA) was 
dissolved in saline. The drug was injected 
intraperitoneal (i.p.) in a volume of 1 ml/kg. 
2.6 Statistics 
All the experiments were double-blind ex-
periments. Data were presented as median 
± MAD. The data were analyzed following 
paired t-test, Wilcoxon Signed rank test or 
Two-way analysis of variance (ANOVA) with 
Fisher's Least Significant Difference (LSD). 
All statistics were made by SPSS, P<0.05 
was considered to be statistically significant. 
3 Results 
We have conducted extensive experiments 
examining the interaction between si-
nomenine and gabapentin in rodent models 
of neuropathic pain and our results showed 
 that there is marked synergistic interaction 
between these two drugs in producing anal-
gesia. 
3.1. Synergistic analgesia effect of 
sinomenine and gabapentin in a 
mouse model of peripheral nerve 
injury. 
As previously reported, mice developed 
chronic hypersensitivity to mechanical stim-
uli (von Frey hair) after sciatic nerve injury 
(SNI) in mice (Hao et al., 2000a). These 
pharmacological experiments were applied 
two weeks after sciatic nerve injury, when 
animal exhibited elevated mechanical sen-
sitivity of the hind paws. The analgesic 
index is paw-withdraw threshold to mechan-
ical stimulation (grams). 
A single dose of p.o. administrated si-
nomenine at 20mg/kg or a single dose of i.p. 
administrated gabapentin at 30mg/kg have 
no significant effect on response threshold 
observed up to 4 hours (tested in every 30-
60min) in SNI mice (Fig. 1A). In low dose 
combination, when gabapentin was first ap-
plied at dosage of 7.5mg/kg, with 
sinomenine administrated at dosage of 
10mg/kg 30-60 min later, no analgesic ef-
fect was observed on response threshold 
up to 4 hours (Fig. 1B). However, when si-
nomenine was applied first and then 
gabapentin was administrated 30-60 min 
later, the combination produced significant 
analgesic effect up to 3 hours (Fig. 1C). 
Three dosages of combination were tested 
in the experiment: “sinomenine 10mg/kg + 
gabapentin 7.5mg/kg”, “sinomenine 
20mg/kg + gabapentin 7.5mg/kg” and “si-
nomenine 20mg/kg + gabapentin 15mg/kg” 
(Fig. 1C). No side effect was observed in all 
combination groups at these dosages. Fur-
ther, the analgesic effect was increased 
Fig. 1 Effect of single applied 20mg/kg p.o. sinomenine or 30mg/kg i.p. gabapentin (A), combination applied 
7.5mg/kg gabapentin 30-60min before 10mg/kg sinomenine(B), combination applied 10, 20mg/kg si-
nomenine 30-60min before 7.5, 15mg/kg gabapentin(C) on hind paw withdrawal threshold to mechanical 
stimulation with von Frey hairs in male C57/BL6 mice with sciatic nerve ischemic injury. N = 6 animals in 
each group, data are presented as median ± MAD. Post-drug time points were compared with pre-drug 
withdrawal threshold at time 0 using Paired t-test, *P<0.05. 
 following by increase in dosages of combi-
nation.  
3.2 Synergistic analgesia effect of 
sinomenine and gabapentin in rats 
with spinal cord injury. 
As previously report, rats developed chronic 
hypersensitivity to mechanical (von Frey 
hair) and cold (ethyl chloride) stimuli after 
spinal cord ischemia injury (SCI) (Hao et al., 
1991, 1992). These pharmacological exper-
iments were applied 4-5 weeks after spinal 
cord ischemia surgery, when animal exhib-
ited hypersensitivity to innocuous 
mechanical and cold stimulation. The anal-
gesic index is vocalization threshold to 
mechanical stimulation (grams) or cold 
scores to cold stimulation.  
A single dose of i.p. administrated si-
nomenine at 20mg/kg or gabapentin at 
30mg/kg did not produce any significant an-
algesia effect against mechanical or cold 
stimulation (Fig. 2A and 2B). However, 
when applied in drug combination, small 
doses of sinomenine combined with 
gabapentin (sinomenine pretreated 30-
60min before gabapentin) produced a 
strong analgesic effect observable even 
longer than 4 hours after drug administra-
tion. Three dosages of combination were 
tested in the experiment: “sinomenine 
5mg/kg + gabapentin 2mg/kg”, “sinomenine 
10mg/kg + gabapentin 4mg/kg” and “si-
nomenine 20mg/kg + gabapentin 7.5mg/kg 
(Fig. 2C and 2D). No side effect was ob-
served in all combination groups at these 
dosages. The analgesic effect was in-
creased following by increase in dosages of 
Fig. 2 Effect of single applied 20mg/kg s.c. sinomenine or 30mg/kg i.p. gabapentin (A and B), combination 
applied 5, 10 and 20mg/kg sinomenine 30-60min before 2, 4 and 7.5mg/kg gabapentin (C and D) on 
vocalization threshold to mechanical stimulation with von Frey hairs or cold score to stimulation with ethyl 
chloride in flank area of male SD rats with spinal cord ischemic injury. N = 7 to 8 animals in each group, 
data are presented as median ± MAD. Post-drug time points were compared with pre-drug vocalization 
threshold at time 0 using Paired t-test, *P<0.05. Two-way ANOVA with Fisher's Least Significant Difference 
(LSD) indicated a significant difference between the groups (F=10.8, P<0.001 for C) 
 combination. 
In addition, simultaneous administration of 
10mg/kg sinomenine and 4mg/kg gabapen-
tin could also produce significant synergistic 
analgesia effect to against both mechanical 
and cold stimulation (Fig. 3A and 3B). No 
observable side effect in rats were pro-
duced. 
3.3 Synergistic analgesia effect of 
repeated administration of si-
nomenine and gabapentin in rats 
with spinal cord injury. 
To study the analgesic effect of chronic ad-
ministration of small doses combination of 
sinomenine and gabapentin in rat model of 
spinal cord injury, we select 10mg/kg i.p si-
nomenine combined with 4mg/kg i.p. 
gabapentin in this pharmacological experi-
ment. The analgesic index is vocalization 
threshold to mechanical stimulation (grams). 
In two rounds of experiments, the combined 
administrations are repeated twice daily and 
sustained for 7days (Fig. 4A) and 14days 
(Fig. 4B). Sinomenine was applied 30-
60min before gabapentin and performed 
with dosing interval of 6 hours per day.  
Fig. 3 Effect of simultaneous administrated 10mg/kg i.p. sinomenine and 4mg/kg i.p. gabapentin on vocali-
zation threshold to mechanical stimulation with von Frey hairs (A) or cold score to stimulation with ethyl 
chloride (B) in flank area of male SD rats with spinal cord ischemic injury. N = 7 to 8 animals in each group, 
data are presented as median ± MAD. Post-drug time points were compared with pre-drug vocalization 
threshold at time 0 using Paired t-test, *P<0.05. 
Fig. 4 Effect of repeated combination of 10mg/kg i.p. sinomenine applied 30-60min before 4mg/kg i.p. 
gabapentin twice/day for 7 days(A) and 14 days(B) on vocalization threshold to mechanical stimulation with 
von Frey hairs in flank area of male SD rats with spinal cord ischemic injury. N=6 rats in each group, data 
were presented as median ± MAD. Baseline and post-drug threshold from D2 to D18 were compared with 
D1 using Wilcoxon Signed Rank test, *P<0.05. Post-drug threshold was compared with baseline value using 
Wilcoxon Signed Rank test, +p<0.05. 
 The repeated combination of 10mg/kg si-
nomenine and 4mg/kg gabapentin last for 7 
or 14days were produced significant anal-
gesic effect against mechanical stimulation. 
More importantly, in the course of chronic 
administration, the pain threshold before the 
administration was also significantly in-
creased, which indicates that the drug 
combination produced a sustained analge-
sia. In about 2 days after termination of last 
drug administration, the pain threshold of 
rats returned to pre-treatment level. The 
drug composition in rats did not produce ob-
servable side effects during chronic 
administration. 
4. Discussion 
The clinical management of chronic pain 
has appeared to be one of the most chal-
lenging health issues, facing lack of new 
strategies. In the present study, we have 
shown that combined therapy of si-
nomenine and gabapentin produced 
synergistic analgesia effect compared to 
monotherapy against neuropathic pain in 
central and peripheral nerve injured rats 
and mice. Moreover, the repeated admin-
istration of sinomenine and gabapentin 
combination produced significant analgesic 
effect against mechanical stimulation, with a 
sustained analgesic effect by increasing the 
baseline threshold even before drug admin-
istration, and no observable side effects. 
These findings strongly advocate the feasi-
bility of applying the combination of 
sinomenine and gabapentin as a novel neu-
ropathic pain therapy, although the 
mechanism of such synergic effect pro-
duced by sinomenine and gabapentin on 
chronic pain is still unknown. 
We have previously demonstrated si-
nomenine analgesic property against 
neuropathic pain (Gao et al., 2013; Gao et 
al., 2014). Despite of the well-defined anal-
gesic efficacy, sinomenine’s mechanism of 
action has not yet been established. One 
possible assumption relies on the neuropro-
tective effect of sinomenine mediated by 
decrease of production of superoxide ions 
through inhibiting the microglial NADPH ox-
idase (Qian et al. 2007) thereby reduce the 
reactive oxygen species (ROS). Moreover, 
sinomenine can excert anti-inflammatory 
property by inhibiting cyclooxygenase 
(COX-2), thereby reducing the synthesis of 
the pronociceptive substance prostaglandin 
E2 (PGE2) (Liu et al., 1994). It is also pos-
sible that sinomenine could reduce 
neuroinflammation through deactivation of 
microglias (Qian et al. 2007), which may 
subsequently help to stablize the micro en-
vironment of the pain relaying neuronal 
structure and reduce the neuronal overacti-
vation. Apart from the neuroprotective and 
anti-inflammatory effects, another explana-
tion refers to the direct antinociceptive 
effects from sinomenine, which can be me-
diated through GABAA receptor (Zhu et al., 
2014), or by blocking the acid-sensing ion 
channel and calcium channels (Wu et al., 
2011). 
GABA is an important inhibitory neurotrans-
mitter in the mammalian central nervous 
system, playing an important role in main-
taining the balance of excitation and 
inhibition. A deficiency in GABAergic input 
will lead to pain, anxiety, restlessness, and 
fatigue. Chronic pain is often associated 
with down-regulated and dis-functional GA-
BAergic system ， while gabapentin can 
mimic GABAergic input (Kuzniecky et al., 
2002), and in turn mitigate the imbalanced 
 GABAergic neurotransmission in such situ-
ation. Whereas, gabapentin’s principal 
proposed mechanism of action is the inter-
action with the alpha 2-delta subunit of L-
type voltage-regulated calcium channels ra-
ther than just enhance GABAergic 
neurotransmission (Striano and Striano, 
2008).  
In the present study, we have shown that in 
rats with neuropathic pain, adequate allo-
dynia reduction could only be observed with 
the dosages larger than 100 mg/kg for 
gabapentin (Hao et al., 2000b) and 40 
mg/kg (Gao et al., 2013) for sinomenine. 
When two agents were combined, we found 
a much less doses (1/10 of the original 
doses for both drugs), at dosage of 10 
mg/kg for gabapentin and 4 mg/kg for si-
nomenine, can achieve the same anti-
nociceptive efficacy. This indicate that 
gabapentin and sinomenine can dramati-
cally potentiate each other's analgesic 
efficacy in combination formula. One possi-
ble mechanism of such potentiated 
combined efficacy is that both sinomenine 
and gabapentin can modulate / partially 
block calcium channels (Wu et al., 2011; 
Striano and Striano, 2008), and enhance 
GABAergic neural inhibition (Zhu et al., 
2014; Kuzniecky et al., 2002), thus worked 
synergically against chronic pain.  
There are established evidences showing 
both morphine and dextromethorphan can 
potentiate gabapentin’s effect on suppress-
ing chronic pain (Gilron et al., 2005). In the 
current study, we found sinomenine having 
similar property to enhance gabapentin’s 
analgesic efficacy. Taking consideration 
also that the structure of sinomenine is 
closely related to morphine and dextrome-
thorphan (Yamasaki, 1976), it is rational to 
postulate that such synergic effect with 
gabapentin depends on shared structure 
between morphine, gabapentin and si-
nomenine, which evidently need to be 
further validated. 
Time is a critical issue when it comes to 
combined drug administration. Sinomenine 
and gabapentin can only provide sufficient 
pain relief when sinomenine was pretreated 
30-60 min before gabapentin application or 
the two drugs applied at the same time. This 
suggest that gabapentin's effect can be 
boosted only with the presence of si-
nomenine, but the opposite scenario does 
not generate synergy. Why in this drug com-
bination, the pretreatment of sinomenine 
but not gabapentin is key to synergy is still 
mysterious to us, however we assume that 
this may be related to the mechanism of ac-
tion of both drugs and their duration of 
effectiveness when applied systemically.  
5. Conclusion 
In conclusion, our study has shown that the 
combined therapy of sinomenine and 
gabapentin has promising synergic effect in 
alleviating neuropathic pain in central and 
peripheral nerve injury in rats and mice 
models, with less dosage and reduced side 
effects. The repeated administration of 
combined therapy also produced significant 
analgesic effect without introducing toler-
ance. This study, together with other studies, 
indicate that compared to single agent, the 
combined therapy entails benefits including 
improved analgesic effectiveness and re-
duced adverse effects with smaller doses of 
individual drugs. However, such drug com-
position and the application criteria need to 
be further validated in clinical studies before 
it can be widely used.  
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Abstract
Background and aims: The clinical management of neu-
ropathic pain remains a challenge. We examined the 
interaction between gabapentin and NMDA receptor 
antagonists dextromethrophan and MK-801 in alleviating 
neuropathic pain-like behaviors in rats after spinal cord or 
sciatic nerve injury.
Methods: Female and male rats were produced with 
Ischemic spinal cord injury and sciatic nerve injury. 
Gabapentin, dextromethorphan, MK-801 or drug combi-
nations were injected with increasing doses. Mechani-
cal response thresholds were tested with von Frey hairs 
to graded mechanical touch/pressure, and ethyl chloride 
spray was applied to assess the cold sensitivity before and 
after injuries.
Results: In spinally injured rats, gabapentin and dex-
tromethorphan did not affect allodynia-like behaviors at 
doses of 30 and 20 mg/kg, respectively. In contrast, com-
bination of 15 or 30 mg/kg gabapentin with dextrometho-
rphan at 10 mg/kg produced total alleviation of allodynia 
to mechanical or cold stimulation. Further reducing the 
dose of gapapentin to 7.5  mg/kg and dextromethorphan 
to 5  mg/kg still produced significant effect. MK-801, 
another NMDA receptor antagonist, also enhanced the 
effect of gabapentin in spinally injured rats. Similar syn-
ergistic anti-allodynic effect between dextromethorphan 
and gabapentin was also observed in a rat model of 
partial sciatic nerve injury. No increased side effect was 
seen following the combination between gabapentin and 
dextromethorphan.
Conclusions: In conclusion, the present study suggested 
that combining NMDA receptor antagonists with gabap-
entin could provide synergistic effect to alleviate neuro-
pathic pain and reduced side effects.
Implications: Combining NMDA receptor antagonists with 
gabapentin may provide a new approach in alleviating 
neuropathic pain with increased efficacy and reduced 
side effects.
Keywords: anti-convulsant; dextromethorphan; MK-801; 
nerve injury; spinal cord injury.
1   Introduction
Anticonvulsants, such as carbamazepine or phenytoin, 
have been traditionally used for the management of neu-
ropathic pain. Their efficacy has, however, not been une-
quivocally established for many types of neuropathic pain 
and they are often associated with side effects [1, 2]. More 
recently, the antiepileptics gabapentin has been increas-
ingly used as an analgesic in neuropathic pain [1–3]. 
Although it was found to exert analgesic effect superior 
to placo in a large number of randomized, placebo con-
trolled, double-blind clinical trials in conditions such as 
postherpetic neuralgia, painful diabetic neuropathy and 
central neuropathic pain, gabapentin only provide some 
degree of pain relief in a minority of neuropathic pain 
patients [4–7].
Another class of compounds believed to be useful 
in neuropathic pain is antagonists of NMDA receptors 
for glutamate [1, 8, 9]. Such promise was derived from 
the well established involvement of NMDA receptors in 
plasticity after injury to the nervous system as well as its 
pivotal role in central sensitization and hyperalgesia [8]. 
However, NMDA antagonists in general produced many 
side effects and clinical trials with several clinically avail-
able compounds with NMDA receptor blocking property in 
neuropathic pain have produced at best conflicting results 
[1, 8–10].
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It is also well established in rodent models that the 
antinociceptive effect of morphine is potentiated by 
NMDA receptor antagonists that is mediated by an inter-
action between the activation of the μ-opioid and NMDA 
receptors at cellular level [11, 12]. NMDA antagonists 
also reversed morphine tolerance [11]. The interaction 
between NMDA receptor antagonists and other analgesics 
is however less known. In the present study, we evaluated 
the analgesic interaction between NMDA receptor antago-
nists, MK-801 and dextromethorphan, and gabapentin 
using two rat models of neuropathic pain after spinal cord 
or sciatic nerve injury.
2   Materials and methods
Male and female Sprague-Dawley rats (Mollegård, 
Denmark) weighing 200–250 g at the start of the experi-
ments were used. All experimental procedures were 
approved by the local research Ethics Committee.
2.1   Photochemically-induced ischemic 
spinal cord injury
Ischemic spinal cord injury was produced in female SD 
rat weighing 200 g according to methods described pre-
viously [13]. In brief, rats were anesthetized with chloral 
hydrate (300  mg/kg, i.p.) and a midline incision was 
made on the skin overlying vertebral segments T 12-L 1. 
The animals were positioned beneath an argon laser 
beam and irradiated for 10  min with the beam directed 
towards vertebral segment T 12 or T 13 (spinal segments L 
3–5). Immediately prior to and 5 min after the start of the 
irradiation, erythrosin B (Red N°3, Aldrich-Chemie, Stein-
heim, Germany) dissolved in 0.9% saline was injected 
intravenously through the tail vein at a dose of 32.5 mg/kg. 
A  tunable argon ion laser (Innova model 70, Coherent 
Laser Product Division, Palo Alto, CA, USA) operating at 
514  nm was used. The average beam output power was 
160 mW. The beam covers the entire width of the vertebra 
and the length is approximately 1–2 mm. After irradiation, 
the wound was closed in layers and the rats were allowed 
to recover. Bladder was empted manually for 1 week.
2.2   Assessment of mechanical and cold 
 sensitivity after spinal cord injury
The behavioral assessments were conducted blindly as 
the groups of drugs administered. Vocalization thresholds 
to graded mechanical touch/pressure were tested with 
calibrated von Frey hairs (ranging from 0.04 to 0.2155 mN, 
Stoelting, Chicago, IL, USA). During testing the rats were 
gently restrained in a standing position and the von Frey 
hair was pushed onto the skin until the filament became 
bent. The frequency of stimulation was about 1/s and at 
each intensity, the stimuli were applied 5–10 times. The 
intensity of stimulation which induced consistent vocal-
ization (>75% response rate) was considered as pain 
threshold.
The response of rats to brushing stimulation was 
tested with the blunt point of a pencil gently stroking the 
skin on the trunk in a rostro-caudal direction. The fre-
quency of the stimulation was about 1 Hz and responses 
were graded with a score of 0 = no observable response; 
1 = transient vocalization and moderate effort to avoid 
probe; 2 = consistent vocalization and aversive reactions 
and 3 = sustained and prolonged vocalization and aggres-
sive behaviors. Normal rats exhibited no reactions to such 
brush stimuli (score 0).
Responses to cold was tested with ethyl chloride spray 
applied to the shaved allodynic skin area. The response 
was graded with a score of 0 = no observable response; 
1 = localized response (skin twitch and contraction), no 
Fig. 1: Effects of gabapentin at 30 mg/kg, dextromethorphan at 
20 mg/kg or combination of the two compounds on vocalization 
threshold to von-Frey hair stimulation in spinally injured rats. The 
data is expressed as median ± MAD (median absolute deviation) and 
6–8 rats were included in each group. * = p < 0.05 compared to time 
0 with Wilcoxon signed-rank test. Friedman ANOVA with repeated 
measures indicated a significant general difference for the three 
drug combination groups (p < 0.01).
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vocalization; 2 = transient vocalization, moderate strug-
gle and 3 = sustained vocalization and aggression. Normal 
rats usually had response score of 0 or 1.
2.3   Photochemically-induced sciatic nerve 
injury
Male SD rats were anesthetized by chloral hydrate 
(300 mg/kg, i.p.) and the left sciatic nerve was exposed. 
The nerve trunk was gently dissected free from the sur-
rounding tissue over a distance of about 1 cm proximal 
to trifurcation. The exposed nerve was irradiated with an 
argon ion laser for 2 min. The irradiation was performed 
with a knife-edged beam across the nerve. Aluminum 
foil was placed under the nerve to isolate the surround-
ing tissue and to reflect light. Just before the irradiation, 
erythrosin B (Aldrich, USA 32.5 mg/kg dissolved in 0.9% 
saline) was injected i.v. via the tail vein. After the surgery 
the wounds were closed in layers and the rats were 
returned to the cages for subsequent behavioral tests.
2.4   Assessment of mechanical sensitivity 
after sciatic nerve injury
The behavioral assessments were conducted blindly as 
the groups of drugs administered. To test of sensitivity to 
mechanical stimulation, the rats were placed in plastic 
cages with a metal mesh floor. The plantar surface of the 
hind paws was stimulated with a set of calibrated von Frey 
hairs (ranging from 0.04 to 0.2155 mN, Stoelting, Chicago, 
IL, USA) with increasing force until the animal withdrew 
the limb. Each monofilament was applied 5 times. The 
withdrawal threshold was taken as the force at which the 
animal withdrew the paw from at least three out of five 
consecutive stimuli.
2.5   Drugs and statistics
Gabapentin, dextromethorphan and MK-801  were 
obtained from Research Biochem Inc. (Natick, MA, USA) 
and dissolved in physiological saline. All drugs were 
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Fig. 2: Effect of gabapentin at 30 mg/kg, dextromethorphan at 20 mg/kg or combination of the two compounds on responses of spinally 
injured rats to brushing stimulation. The responses were graded and number of rats exhibiting different level of responses were shown. 
* = p < 0.05 compared to time 0 with Wilcoxon signed-ranks test.
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injected i.p. in a volume of 0.1  mL/kg. The behavioral 
assessments were conducted blindly. Data are expressed 
as median ± median absolute deviation (MAD) and ana-
lyzed with Friedman one way analysis of variance for 
repeated measurements and Wilcoxon signed-ranks test.
3   Results
3.1   Spinally injured rats
As previously described, some spinally injured rats devel-
oped allodynia-like behavior manifested as reduction 
in vocalization threshold to mechanical touch stimu-
lation applied by the von-Frey hairs or by brush and as 
increased response to cold stimulation applied by ethyl 
chloride spray. And saline treatment has no effect on 
either mechanical or cold sensitivity on our neuropathic 
pain models [13–15].
I.p. dextromethorphan or gabapentin did not alleviate 
allodynia-like behaviors at the doses up to 20 or 30 mg/kg, 
respectively (Figs.  1–3). Further increasing the dose of 
dextromethorphan or gabapentin produced numerous 
side effects, including sedation and motor impairment 
for gabapentin and hyperactivity for dextromethorphan. 
Combining gabapentin (7.5, 15 or 30  mg/kg) with low 
doses of dextromethorphan (5 or 10 mg/kg) significantly 
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Fig. 3: Effect of gabapentin at 30 mg/kg, dextromethorphan at 20 mg/kg or combination of the two compounds on responses of  spinally 
injured rats to cold stimulation. The responses were graded and number of rats exhibiting different level of responses were shown. 
* = p < 0.05 compared to time 0 with Wilcoxon signed-ranks test.
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increased vocalization threshold to von-Frey hair stimula-
tion (Fig. 1), reduced and normalized increased response 
to brush (Fig. 2) or cold (Fig. 3) stimulation. The anti-
allodynic effect of dextromethorphan and gabapentin 
is long-lasting, but reversible. At doses used, gabapen-
tin, dextromethorphan or combination did not produce 
observable side effects, such as sedation, motor impair-
ments or hyperactivity.
I.p. MK-801 at 0.05 or 0.1  mg/kg also did not affect 
mechanical allodynia-like behavior in spinally injured rats 
whereas combination of small doses (0.01 or 0.05 mg/kg) 
of MK-801  with 15  mg/kg gabapentin again significantly 
increased vocalization threshold to von-Frey stimulation 
(Fig. 4). The cold allodynia was also similarly reduced (not 
shown).
3.2   Sciatic nerve injury
Rats subjected to ischemically-induced sciatic nerve 
injury developed mechanical hypersensitivity seen as 
bilaterally decreased paw withdrawal threshold to von-
Frey hair stimulation which peaked at 1–2  weeks when 
the experiments were conducted. The mechanical hyper-
sensitivity is more severe on the ipsilatera side to the 
irradiation than the contralateral side and the data from the ipsilateral were presented. I.p. dextormethorphan or gabapentin did not affect mechanical allodynia in sciatic 
nerve injured rats in the present experiments as doses up 
to 40 or 100  mg/kg despite the presence of side effects 
(Fig. 5). In contrast, combining gabapentin 30 mg/kg with 
20 mg/kg dextromethorphan significantly increased paw 
withdrawal threshold to von-Frey stimulation in nerve 
injured rats (Fig. 5).
4   Discussion
The present results showed that combining NMDA recep-
tor antagonists and gabapentin produced synergistic 
antiallodynic effect in two rat models of neuropathic 
pain after spinal cord or sciatic nerve injury. The effect of 
the combination is clearly synergistic rather than addi-
tive since either drug along did not produce any effects 
at doses equal or even larger than that of the combina-
tion [16, 17]. At effective doses, the combination did not 
produce increased side effects in comparison to either 
drug alone. Thus, the present results support a potential 
clinical application of this combination strategy, particu-
larly with NMDA antagonists that are clinically available, 
in treating patients with neuropathic pain of central and/
or peripheral origins.
Fig. 4: Effect of MK-801 at 0.05 or 0.1 mg/kg or combination 
with MK with gabapentin 15 mg/kg on vocalization threshold of 
spinally injured rats to von Frey stimulation. The data is shown as 
median ± MAD (median absolute deviation) and * = p < 0.05 com-
pared to time 0 with Wilcoxon signed-ranks test. Friedman ANOVA 
with repeated measures indicated a significant general difference 
for the two drug combination groups (p < 0.01).
Fig. 5: Effects of gabapentin at 100 mg/kg, dextromethorphan 
at 40 mg/kg or combination of dextromethorphan 20 mg/kg and 
gabapentin 30 mg/kg on paw withdrawal threshold after partial 
sciatic nerve injury. The data is expressed as median ± MAD 
(median absolute deviation) and 6–8 rats were included in each 
group. * = p < 0.05 compared to time 0 with Wilcoxon signed-
rank test. Friedman ANOVA with repeated measures indicated a 
 significant general difference for the drug combination groups 
(p < 0.01).
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The mechanisms by which synergism between dex-
tromethorphan and gabapentin occurs are unclear. 
The analgesic effect of gabapentin may be related to its 
binding to the α2δ subunit of the voltage-dependent 
calcium channels (VDCCs) [18, 19]. Thus, such synergism 
may be derived from a simultaneous reduction in calcium 
entry through blockade of VDCCs and NMDA receptor/
channels. In this context, it is noteworthy that gabapen-
tin per se often produced limited effect on various types 
of Ca2+ currents [20–23]. In addition, such interaction may 
also occur directly at the NMDA receptor complex. Previ-
ous work has shown that the anti-hyperalgesic effect of 
gabapentin was blocked by D-serine, an agonist at the 
glycine site of the NMDA receptor [24, 25]. The direct effect 
of gabapentin on NMDA receptor is, however, an enhance-
ment of NMDA-evoked current in isolated neurons that 
may be difficult to reconcile with its analgesic effect [26, 
27]. Gabapentin is also able to reduce glutamate release in 
some systems that may also contribute to its interaction 
with an additional blockade of the NMDA receptors [28, 
29]. Finally, although dextormethorphan can also act on 
VDCCs [30], the fact that MK-801 also enhances the effect 
of gabapentin made it unlikely that such interaction take 
place solely at the VDCCs.
It is interesting to note that the synergism between 
dextromethorphan and gabapentin produces larger effect 
in spinally injured rats than in rats with sciatic nerve 
injury. This is possibly due to the fact that both drugs are 
less potent in the periphery vs. central model [17, 31] and 
may reflect different mechanisms for these two neuro-
pathic pain models. Nonetheless, it is tempting to suggest 
that this combination may be particularly useful in treat-
ing spinal cord injury pain, a difficult clinical problem 
[32]. Our results also support the clinical observation [9] 
in which they showed that combination of dextrometho-
rphan and gabapentin alleviated neuropathic pain in 
patients with spinal cord injury.
5   Conclusion
In conclusion, the present study suggested that combin-
ing NMDA receptor antagonists with gabapentin could 
provide a new approach in alleviating neuropathic pain 
with increased efficacy and reduced side effects.
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